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Abstract

SELECTIVE NON-PEPTIDE MU-OPIOID RECEPTOR ANTAGONISTS:
DESIGN, SYNTHESIS AND PHARMACOLOGICAL STUDIES
By Lindsey C. K. Aschenbach, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2008
Major Director: Dr. Yan Zhang, Assistant Professor
Department of Medicinal Chemistry
There are currently many opioid agonists available for clinical use as analgesics.
However, many of these opioid agonists have notorious side effects including respiratory
depression and may lead to addiction and dependence. Problems associated with these
opioid agonists are determined to come from their interactions with the mu-opioid
receptor. Opioid antagonists, such as naltrexone, have shown to aid in the treatment of
opioid addiction. Although naltrexone has high affinity to the mu-opioid receptor, it
lacks selectivity. Novel selective mu-opioid receptor antagonists were designed based on
the identification of important pharmacophore elements in several known mu-opioid
receptor agonists and antagonists.
biological

assays

were

These compounds were synthesized and in vitro

conducted
xviii

to

determine

their

affinity

to

xix
all three opioid receptors. Also, molecular modeling studines were conducted to help
visualize the interactions between the mu-opioid receptor and these ligands. Finally, four
lead

compounds

have

been

identified

for

further

optimization.

I. Introduction
Ancient civilizations have used extracts from the poppy flower for analgesic
purposes. Around 300 B.C. Theophrastus described the analgesic use of opium in the
“Inquiry of Plants”. Opium was a crude extract from the unripe seedpod of the poppy
flower, Papaver Somniferum. Morphine is the main active ingredient of opium and was
isolated by Serturner in 1803. Later, other morphine-like alkaloids, such as thebaine and
codeine, were isolated from the same resource. Morphine is still the most commonly
used opioid analgesic in clinical settings.1
Morphine produces many effects including analgesia, which makes it useful to
treat post-operation and chronic pain. However, morphine also has adverse side effects
such as respiratory depression, pancreatitis, renal failure, chemical toxicity for patients
with low tolerability, and raised intracranial pressure that can lead to head injuries. Most
significantly, morphine is highly addictive both physically and psychologically.2
Opioids have been associated with abuse and addiction problems for a long time.
However, it has become more prominent over the last couple of centuries, especially
since the introduction of the hypodermic needle in the 1950s. Long-term use of opioids
may lead to addiction that can result in a compulsive need for opioids. According to the
National Survey on Drug Use and Health (NSDUH), in 2005 about 2.2 million people

1

2
used prescription analgesics for non-medical purposes for the first time. As of 2007, it is
3

estimated about 16 million people worldwide abuse opioids.4 Opioid dependency and
addiction can be treated through detoxification or drug replacement therapy.
Morphine, as well as other opioids, mainly acts on the opioid receptors in the
central nervous system. There are three major opioid receptors including mu, kappa and
delta. All three opioid receptors are involved in analgesia. However, it has been shown
that the analgesic effect and adverse side effects of morphine are primarily due to its
interaction with the mu-opioid receptor. For example, it was found that the analgesic and
addictive properties of morphine is abolished in mu-opioid receptor knock-out mice.5
Therefore, the characterization of the mu-opioid receptor is essential for understanding of
morphine’s analgesic mechanism and addictive potential.
Opioid antagonists have played important roles in the pharmacological studies of
opioid receptors. Receptor selective antagonists are preferred in characterizing each type
of opioid receptors. Due to the role of the mu-opioid receptor in analgesia and drug
addiction,

highly

selective

mu-opioid

receptor

antagonists

are

very

useful

pharmacological tools in the study of the mu-opioid receptor structure-activity
relationship.
Naltrexone, a non-peptide opioid antagonist, is a long-acting and reversible opioid
ligand used for the management of alcohol and opioid dependence. Naltrexone can also
be used to treat other types of addiction including compulsive shopping and gambling. It
has been shown to promote abstinence and prevent relapse.6 However, naltrexone may
also carry some side effects including dysphoria, depression, pulmonary edema and

7,8

cardiac arrhythmias.

3
These side effects may be related to the low selectivity of

naltrexone to the opioid receptors.9 On the other hand, there are a couple of selective
peptidyl mu-opioid receptor antagonists available, including CTOP and CTAP.
However, these two compounds are peptides and may undergo metabolic inactivation.10
Therefore, the development of highly selective non-peptide mu-opioid receptor
antagonists is needed to help alleviate any adverse effects seen by opioid antagonists with
low selectivity.
The ability for these ligands to be reversible is also very important in the design
of opioid antagonists. Reversible opioid antagonists will temporarily block the opioid
receptor and can be easily washed out of the binding locus during pharmacological
studies. However, irreversible antagonists will covalently bind to the receptor and will
inactivate the receptor indefinitely. Therefore, in certain cases reversible mu-opioid
receptor antagonists are preferred in order to study the mu-opioid receptor.
Although naltrexone has some problems associated with its low selectivity to the
opioid receptors, it may be an ideal template for the design of selective mu-opioid
receptor antagonists. Naltrexone has subnanomolar to nanomolar affinity to the three
opioid receptors and shows mild selectivity for the mu- and kappa-opioid receptors over
the delta-opioid receptor. It may be helpful to maintain the high affinity for the muopioid receptor by utilizing naltrexone as the backbone in the design of new mu-opioid
receptor antagonists.
Previous site-directed mutagenesis and molecular modeling studies have shown
that certain amino acid residues are critical for ligand selectivity. For example, amino

4
acid residue Trp318 located in extracellular loop (EL) 3 of the mu-opioid receptor is a
major contributor to the selectivity of mu-opioid receptor antagonists to the mu-opioid
receptor.11 It is important to note that Trp318 is not conserved in the delta- and kappaopioid receptors.11 Therefore, the addition of certain structural features to the backbone
of naltrexone that might interact with EL3 of the receptor may lead to some novel
antagonists with high selectivity to the mu-opioid receptor.
The focus of this project is the design, chemical synthesis and pharmalogical
evaluation of selective and reversible non-peptide mu-opioid receptor antagonists that
carry structural features to interact with EL3 of the mu-opioid receptor. The molecular
design of the compounds is based on our previous molecular modeling studies of some
selective mu-opioid receptor agonists and irreversible mu-opioid receptor antagonists.
Based on the information obtained from the molecular modeling studies, a series of new
ligands will be designed as mu-opioid receptor antagonists. The newly designed ligands
will be chemically synthesized and further characterized through various in vitro
pharmacology studies, including competition radioligand binding assays for the three
opioid receptors and functional assays to determine the possible efficacy of the ligands.
The development of highly selective, non-peptidyl, and reversible mu-opioid
receptor antagonists will benefit the treatment of dependence and addiction on opioids
with fewer side effects.

Furthermore, these compounds can be used as probes to

characterize the mu-opioid receptor and in the long run benefit the development of new
analgesics with decreased adverse side effects.

II. Background
1.

Brief Introduction to the Mu-Opioid Receptor
The existence of different types of opioid receptors was proposed in 1973 by

Terenius and later confirmed by other research groups using stereospecific radioligand
binding assays.12-14 In 1981, three distinct types of opioid receptors were identified and
classified as mu-, delta- and kappa-opioid receptors based on results of the behavioral and
bioassay studies.15,16 All three opioid receptors have been cloned and the amino acid
residue sequences of their cDNA has been determined between 1993 and 1994.17 Further
pharmacological characterization revealed that the mu-opioid receptor mediates the
analgesic effect of morphine.18,19

1.1

Structure and Signal Transduction of the Opioid Receptor
The opioid receptors belong to the G-protein coupled receptor (GPCR)

superfamily in the rhodopsin subclass.

Opioid receptors (Figure 1) are integral

membrane proteins made up of seven transmembrane (TM) spanning alpha-helices
connected by three intracellular loops (IL) and three extracellular loops (EL).20

5

6

Figure 1. Model of the human mu-opioid receptor.21

The seven transmembrane regions of the receptor allow signal transduction for
many small molecules, peptide transmitters, and modulators. The interaction of the
receptor with the guanine nucleotide-binding proteins (G-proteins) mediates signaling for
opioid receptors.22 The G-protein is a heterotrimeric protein composed of three subunits,
the Gα, Gβ and Gγ subunits. Opioid receptors interact preferentially with the pertussis
toxin sensitive G-proteins of the Giα and Goα families.22
The Gα, Gβ and Gγ subunits activate when an agonist binds to the receptor and a
conformational change takes place (Figure 2). This conformational change promotes the
exchange of GDP with GTP at the Gα subunit. The G-protein dissociates into a GTPbound Gα subunit and a Gβγ subunit and both will activate downstream second messenger

7
pathways. Deactivation of the receptor occurs when GTPase located in the Gα domain
hydrolyzes the GTP subunit to a GDP subunit followed by re-association with the Gβγ
subunit.23

Figure 2. The activation cycle of a GPCR.24

Activation of the opioid receptor mediates the inhibition of adenylyl cyclase
activity caused by the GTP-bound Gα subunit.25 The acute inhibition of adenylyl cyclase
reduces the production of cyclic adenosine monophosphate (cAMP) resulting in the
reduction of voltage-dependent current and neurotransmitter release. The threshold of
voltage-dependent ion channels shifts to more negative potentials when cAMP levels
decrease. Therefore, there is a decrease in neuron excitability.26 In addition, the Gβγ
subunit of opioid receptors mediates the reduction of cellular excitability through

8
membrane hyperpolarization caused by the activation of potassium conductance and the
inhibition of voltage-gated calcium channels.27,28

1.2

Distribution of the Mu-Opioid Receptor in the CNS
Anatomical localization of opioid receptors was first investigated using

radioligand

autoradiography

techniques.29

Later,

cloning

technology

and

immunohistochemical analysis has allowed higher resolution to investigate anatomical
distributions and expression levels of opioid receptors at the plasma membrane.30,31 The
opioid receptors are widely distributed in the central nervous system (CNS) and in the
peripheral sensory and autonomic nerves.32 Studies have shown that the mu-opioid
receptor is expressed throughout the CNS including the cortex, hypothalamus, midbrain
periaqueductal gray (PAG) matter, and rostral ventromedial medulla (RVM).33,34 Muopioid receptors control the pain transmission pathway directly by acting in the
superficial layers of the dorsal horn.34 At the same time, the mu-opioid receptor as well
as the kappa-opioid receptors are widely distributed on the wall of the gastrointestinal
tract.35

1.3

Pharmacological Effects Mediated by the Mu-Opioid Receptor
Activation of opioid receptors by endogenous peptides is involved in regulation of

both behavioral and homeostatic functions, including nociception, food intake,
respiration, reward mechanisms, and gastrointestinal motility.36

Through the use of

transgenic mice lacking each opioid receptor, the mu-opioid receptor was confirmed to

9
mediate the acute effects of most clinically relevant opioid drugs including analgesia,
respiratory depression, locomotor stimulation, and chronic effects such as physiological
withdrawal signs.37

The activation of mu-opioid receptors specifically mediates the

analgesic actions of opioid agonists.34

The role of endogenous opioids in pain

suppression provides an important insight into the biology of opioid analgesics.
Morphine, the prototypical opioid analgesic, does not simply inhibit the paintransmission pathways; it mimics the action of the endogenous opioid peptides released
in response to a specific stimulus such as pain.34
It is well known that the chronic use of opioid analgesics results in the
development of tolerance, which is defined as a loss of effect following repeated
treatments such that a higher dose is required for an equivalent effect.34 Dependence is
another result from chronic use of opioid analgesics. Interestingly, it has been proposed
that dependence occurs with the discontinuation of opioid drugs and will manifest itself
as a withdrawal syndrome.18

2.

Mu-Opioid Receptor Antagonists
Mu-opioid receptor agonists like morphine have been used for many years and are

still used as the first line therapy in the treatment of moderate to severe pain.36 Despite
the clear benefits from the use of mu-opioid receptor agonists, severe side effects have
been associated with these drugs. These side effects, including respiratory depression,
addiction and dependence, associated with opioid agonists have been determined to come
from the interactions with the mu-opioid receptor.
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At present, there are several pharmacotherapies available for maintenance
treatment of opioid addiction.

These pharmacotherapies include opioid receptor

antagonists with low selectivity like naltrexone and naloxone.

Although they are

commonly used for treatment of the adverse effects associated with mu-opioid receptor
agonists, naloxone and naltrexone have some side effects due to their lack of selectivity.
Therefore, selective opioid antagonists are important in order to eliminate interactions
with other opioid receptors.
Cyprodime is another opioid antagonist used mainly in pharmacological studies
due to its moderate selectivity to the mu-opioid receptor. However, cyprodime has lower
affinity to the mu-opioid receptor compared to naloxone and naltrexone. Other types of
mu-opioid receptor antagonists include peptide ones, such as CTAP and CTOP, and
irreversible non-peptidyl ones, e.g. β-FNA. These peptides and irreversible non-peptidyl
compounds are not used for medicinal purposes due to various issue associated including
rapid metabolism and inactivation of the receptor indefinitely.

Therefore, the

development of reversible and selective non-peptidyl mu-opioid receptor antagonists will
be beneficial in the treatment of the adverse effects associated with opioid agonists.

2.1

Prototypical Mu-Opioid Receptor Agonist: Morphine
Activation of the mu-opioid receptor by opioid agonists has been associated with

various undesirable side effects.

Some of these side effects include dependence,

sedation, respiratory depression, seizure, constipation, and opioid bowel dysfunction.38
Despite these serious effects associated with opioid agonists such as morphine (1; Figure
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3), the rate of their use for moderate to severe pain has steadily increased in recent
years.39
N
OH

HO

O

OH

1

Figure 3. Structure of the mu-opioid receptor agonist: morphine (1).

Morphine is the principal active agent of opium and is a very potent mu-opioid
receptor agonist (Table 1).36 Morphine acts directly in the CNS to relieve pain and is the
gold standard used to judge the analgesic properties of other mu-opioid receptor
agonists.38

Table 1. Binding affinities of morphine (1) for the opioid receptors.36

1

Ki μ (nM)

Ki δ (nM)

Ki κ (nM)

Ratio δ/μ

Ratio κ/μ

1.80

160

47.0

88.9

26.1

The discovery of new pain medications has occupied both the academic
community and pharmaceutical industry for the past two decades with little success.38
Morphine and related compounds remain the drugs of choice for the treatment of
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moderate to severe pain in the U.S. Furthermore, many of the newer drugs are either in
clinical trials or currently on market in alternative dosage forms of classical opioids.40

2.2

Naltrexone and Naloxone: Non-selective Opioid Receptor Antagonists
Opioid antagonists are commonly used as rescue medications to counteract the

adverse side effects induced by opioid agonist overdose, mainly respiratory depression.
They are also used clinically in the treatment of opioid dependence and alcoholism.41 To
this date, there are only two FDA approved mu-opioid receptor antagonists, naloxone and
naltrexone, for the treatment of adverse effects associated with opioid agonists.38
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Figure 4. Structures of naloxone (2), naltrexone (3), naltrexone’s metabolite 6β-naltrexol
(4), and buprenorphine (5).
Naltrexone (3; Figure 4) is a competitive opioid receptor antagonist with low
selectivity that falls into the morphinan structural series of opioids.

Naltrexone

promiscuously binds with high affinity to the mu- and kappa-opioid receptors and binds
with lower affinity to the delta-opioid receptor (Table 2).42 Naltrexone has been found to
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be orally active with greater potency and longer duration of action than its counterpart
naloxone (2; Figure 4).43

When naltrexone is administered orally, about 60% is

eliminated within 42 h after administration.44 The mean naltrexone plasma levels decline
very slowly and naltrexone still can be seen in the plasma 96 h after administration.45
These properties make naltrexone suitable for the treatment of opioid dependence and
provide an effective treatment for addicted patients.46 For over a decade, naltrexone has
also been an approved treatment for alcohol addiction, although oral administration leads
to poor patient compliance.47 When administered to an opioid-dependent person, acute
withdrawal effects will precipitate.4 When naltrexone is administered orally, only 40% of
the dose is bioavailable due to the first pass metabolism.48 In addition, poor compliance
may be due to elevated plasma concentrations of the first pass metabolite 6β-naltrexol (4;
Figure 4). This metabolite has been linked to increased incidence of side effects and
treatment dropout.49
Naloxone is administered intravenously to reverse respiratory depression
associated with overdose and analgesia from opioid agonists. Although naloxone has
lower affinity to the mu-opioid receptor compared to naltrexone, it still has the ability to
precipitate withdrawal effects similar to naltrexone. The oral bio-availability of naloxone
is poor (only 2%) due to extensive first pass metabolism.50
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Table 2. Binding affinities of naloxone (2) and naltrexone (3) for the opioid
receptors.42,51
Ratio δ/μ
Ratio κ/μ
Ki μ (nM)
Ki δ (nM)
Ki κ (nM)
2

1.90

32.6

3.06

17.2

1.61

3

0.11

60.0

0.19

545

1.72

The FDA recently approved Vivitrol, an extended-release formulation of
naltrexone that is administered intramuscularly, for the treatment of alcohol addiction.
The administration of Vivitrol results in lower plasma concentration of 6β-naltrexol,
which leads to better patient compliance and a reduced side effect profile.47 Other
treatments for opioid addiction include combination of naltrexone and buprenorphine.
Buprenorphine (5; Figure 4) is a mu-opioid receptor partial agonist and allows a decrease
in withdrawal symptoms during opioid detoxification since naltrexone may displace
buprenorphine from the mu-opioid receptor more gradually due to similar affinities.52
Although naloxone and naltrexone are effective treatments for a large number of
disorders, including alcoholism and opioid dependence, they still have several
pharmacokinetic issues. Naloxone has very poor oral bioavailability and a short halflife.53 On the other hand, naltrexone is associated with poor compliance due to the
formation of the metabolite 6β-naltrexol.49 Both naltrexone and naloxone show low
selectivity to the mu-opioid receptor exclusively and this may lead to other
complications. Cardiac arrhythmias and pulmonary edema may be linked to naloxone’s
interaction with the kappa-opioid receptors.54 Also patients receiving naltrexone for
opioid dependence exhibited higher than expected rates of overdose and suicide while
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some reports have been linked to depression and dysphoria due to naltrexone’s
interaction with the delta-opioid receptor.55

2.3

Cyprodime: Moderately Selective Mu-Opioid Receptor Antagonist
Unlike naloxone and naltrexone that lack selectivity to the mu-opioid receptor,

cyprodime (6; Figure 5) is a moderately selective mu-opioid receptor antagonist in vivo
(Table 3).56 Cyprodime has been labeled with tritium resulting in a selective mu-opioid
receptor radioligand with high affinity that has potential to be used as tool in probing muopioid receptor mechanisms. Although cyprodime is more selective for the mu-opioid
receptor over the delta- and kappa-opioid receptors, it shows lower affinity for the muopioid receptor compared to naloxone and naltrexone. Further studies based on the
structure profile of cyprodime did not yield any more selective mu-opioid receptor
antagonists with higher affinity to the mu-opioid receptor.57

N
OCH3

HO

OCH3

O

6

Figure 5. Structure of the mu-opioid receptor antagonist: cyprodime (6).
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Table 3. Binding affinities of cyprodime (6) for the opioid receptors.56

6

2.4

Ki μ (nM)

Ki δ (nM)

Ki κ (nM)

Ratio δ/μ

Ratio κ/μ

5.40

245

2187

45.4

405

Selective and Irreversible Mu-Opioid Receptor Antagonists
Through the use of selective or irreversible opioid antagonists as probes, opioid

receptors and their functional mechanisms can be characterized. The use of selective or
irreversible antagonists allows for elimination of a particular receptor type. Then the
pharmacological properties of the remaining receptor types can now be observed.58,59
Selective irreversible antagonists can be used in combination with agonists to estimate
the relative efficacy and affinity of opioid agonists. The most widely used irreversible
mu-opioid receptor antagonist is beta-funaltrexamine.60
β-Funaltrexamine (β-FNA, 7; Figure 6) was described by Portoghese in 1981 as
the first selective mu-opioid receptor antagonist.61 β-FNA binds to all three opioid
receptors with high affinity. However, β-FNA is an irreversible opioid antagonist only at
the mu-opioid receptor in vitro, which acts as a site-directed alkylating agent that binds
covalently to the mu-opioid receptor.61 The ability of β-FNA to alkylate the mu-opioid
receptor selectively leads to depletion of the mu-opioid receptor population.38 β-FNA has
been widely employed as a tool in the investigation of opioid receptor mechanisms.62
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Figure 6. Structure of β-FNA (7).

Highly selective and irreversible ligands such as β-FNA are widely used as
affinity labels. The design of β-FNA involved the attachment of chemically selective
Michael acceptor group to a naltrexone-derived antagonist pharmacophore.63 Several
factors need to be considered when creating an affinity label. These factors include
affinity of the ligand for the receptor recognition site, the location of the electrophilic
center of the ligand, and the reactivity and selectivity of the electrophilic group.62
Therefore, two consecutive recognition steps are involved in the covalent bonding and
the proper orientation of the ligand with the receptor.64 The use of β-FNA illustrates that
mu-opioid receptor agonists and antagonists have different binding sites.

The pre-

treatment with a mu-opioid receptor agonist, such as morphine, did not protect the
receptor from β-FNA. However, the introduction of a reversible mu-opioid receptor
antagonist, such as naltrexone, effectively protected the receptor from alkylation by βFNA.65
The replacement of the 14-hydroxyl group of naltrexone with an amino group
creates 14-aminonaltrexone (8; Figure 7), which displays potent antagonist activity both
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in vivo and in vitro.38 The acylation of the 14-amino group leads to two more irreversible
mu-opioid receptor antagonists, clocinnamox (C-CAM, 9; Figure 7) and methocinnamox
(M-CAM, 10; Figure 7).66 Unlike β-FNA, both C-CAM and M-CAM act as potent
opioid antagonists to all three of the opioid receptors.65
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Figure 7. Structure of irreversible mu-opioid receptor antagonists: 14-aminonaltrexone
(8), clocinnamox (9), and methocinnamox (10).
The use of selective and irreversible antagonists for the mu-opioid receptor limits
their use since they bind covalently with the receptor. Therefore, reversible antagonists
would be preferred since they temporarily “knock-out” the receptors during
pharmacological studies and can be washed out from the binding locus to revive the
receptor.
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2.5

Selective Peptidyl Mu-Opioid Receptor Antagonists
Somatostatin is a widely distributed regulatory peptide that binds to various

somatostatin receptors within the CNS and peripheral nervous system and is involved in
many biological processes including binding to the mu-opioid receptor.67,68 Somatostatin
was used as a conformational template centered on the tetrapeptide sequence Phe-D-TrpLys-Thr for the design of a series of compounds that contains a β-turn that was found to
be potent to the mu-opioid receptor.69 From the conformational template of somatostatin
two compounds of penicillamine-containing octapeptides were designed and synthesized,
D-Phe-C[Cys-Tyr-D-Trp-Orn-Thr-Pen]-Thr-NH2 (CTOP, 11; Figure 8) and D-PheC[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 (CTAP, 12; Figure 8).70

Both compounds

contain a disulfide linkage between the cysteine and penicillamine that provided a useful
approach in improving selectivity of flexible peptides.70 The additional conformational
constraint allows for an increase in molecular rigidity and an increase in metabolic
stability compared with other endogenous opioid peptides.10 Radiolabeled CTAP has
been shown to be stable in the blood and serum of rats with a half-life of 500 min. The
increased stability of CTAP is probably due to the penicillamine-cysteine disulfide
linkage that allows for CTAP to become conformationally constrained and biologically
active.71

20
S

S
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Figure 8. Structure of selective peptidyl mu-opioid receptor antagonists: CTOP (11) and
CTAP (12).
Although CTOP and CTAP are based on the somatostatin hormone, they both act
as mu-opioid receptor antagonists with low affinity to the somatostatin receptor (Table
4).72 CTAP has shown to reduce antinociception in mice and block the mu-opioid
receptor without causing severe withdrawal symptoms.73 The use of radiolabeled CTAP
has demonstrated its ability to cross the blood brain barrier (BBB) at therapeutic levels.71
Although CTAP has shown some promise as a selective mu-opioid receptor antagonist
compared to natural peptides, however, CTAP is also selective to the somatostatin
receptor. Even though CTAP is more stable compared to endogenous opioid peptides, it
is still vunerable to enzymatic degradation to a lesser extent.10,74

Table 4. Binding affinities of CTOP (11) and CTAP (12) for the opioid receptors.75,76
Ki μ (nM)

Ki δ (nM)

Ki κ (nM)

Ratio δ/μ

Ratio κ/μ

11

0.18

>1,000

>1,000

>5,555

>5,555

12

2.30

365

>10,000

159

>4,348
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Since pharmacological studies require both in vivo and in vitro activity, the use of
selective mu-opioid receptor peptides such as CTOP and CTAP are not as desirable as
non-peptidyl mu-opioid receptor antagonists since they have a shorter half-life.
Therefore, non-peptidyl mu-opioid receptor antagonists are preferred since they have the
ability to penetrate the CNS and are less vunerable to metabolic inactivation compared to
peptides.

3.

Application of the “Message-Address” Concept in the Design of Kappa-

Opioid Antagonists
Progress in opioid research has relied on the use of non-selective opioid
antagonists like naloxone and naltrexone. Both, naloxone and naltrexone are frequently
used in the verification of opioid receptor interactions since they can induce antagonism
with all three opioid receptors.77 Since the recognition of multiple opioid receptor types,
the development of selective antagonists as tools to determine the selectivity of opioid
agonists has become increasingly important.9
The “message-address” concept has been used to design non-peptidyl selective
kappa-opioid receptor antagonists like norbinaltorphine (Nor-BNI, 13; Figure 9) and
GNTI (14; Figure 9) as tools in opioid research.9 Following this concept may allow the
design of new selective mu-opioid receptor antagonists.
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Figure 9. Selective kappa-opioid receptor antagonists: norBNI (13) and GNTI (14).

3.1

Message-Address Concept
Schwyzer first proposed the “message-address” concept in his analysis of the

structure-activity relationship of ACTH, adrenocorticotropic hormone, and related
hormones.78 Peptide hormones within the same class contain a “message” sequence and
an “address” sequence of amino acid residues, each being sequential and close to one
another in the peptide chain.

The message component is responsible for signal

transduction, while the address component provides additional binding affinity and is not
essential for the transduction process.79 Therefore, each compound will contain a unique
address component linked to a common message recognition component (Figure 10).80,81
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Figure 10. Message-address concept. This concept is the basis for selectivity for ligands
to a particular subtype of receptor.82
3.2

Design of Selective Kappa-Opioid Receptor Antagonist
The “message-address” concept has been used to demonstrate opioid ligand

selectivity. First, this concept was enriched so that the “message” component is similar
for all the opioid receptor subtypes. Second, the “address” component is the primary
determinant of selectivity among receptor subtypes.

GNTI (14, Figure 11), 5’-

guanidinonaltrindole, was one of the first selective kappa-opioid receptor antagonists
designed utilizing the “message-address” concept.83
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Figure 11. The conformational analysis of GNTI (14).

The “message” component of GNTI consists of the morphinan moiety; the
“address” component consists of the guanidine moiety. The guanidine moiety confers the
selectivity of GNTI to the kappa-opioid receptor. The indole ring acts as a “spacer” used
to connect the “message” and “address” components. GNTI is 5-fold more potent and
selective than the prototypical kappa-opioid receptor antagonist norBNI.82
Molecular modeling studies of GNTI with the kappa-opioid receptor suggested
the involvement of Glu297 in the binding locus, which is located on the top of TM6.
Since Glu297 is an acidic amino acid residue, it may interact with the guanidine moiety
of GNTI. The mutation of Glu297 to an alanine amino acid residue dramatically reduced
the affinity of GNTI to the kappa-opioid receptor.59,84 Therefore, Glu297 is important for
the recognition and selectivity of GNTI in the binding pocket of the kappa-opioid
receptor.85
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Another site-directed mutagenesis study was conducted to determine the
significance of the acidic amino acid residue Glu297 for the selectivity of GNTI and
norBNI to the kappa-opioid receptor over the mu-opioid receptor. The study involved the
mutation of the amino acid residue Lys303 in the mu-opioid receptor into a glutamate
residue (K303E). Lys303 in the mu-opioid receptor was found to be in an equivalent
position compared to Glu297 in the kappa-opioid receptor.

It was found that the

replacement of the lysine residue with the glutamate residue allowed the binding of
norBNI and GNTI with much higher affinity to the mutated mu-opioid receptor then to
the wild mu-opioid receptor.84
Alternatively, when Glu297 was mutated to a lysine residue in the kappa-opioid
receptor (E297K), the binding affinities for both GNTI and norBNI were diminished to
the mutated kappa-opioid receptor (Table 5). These studies suggest that the kappaopioid receptor and the mutated mu-opioid receptor contain similar binding sites that may
be the recognition or “address” site. These binding sites were able to recognize the
positively charged group in GNTI and norBNI.84 This study highlights the significant
role of the acidic amino acid residue, Glu297, of the kappa-opioid receptor in conferring
ligand selectivity.
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Table 5. Effects on the binding affinity of mutated amino acid residues Glu297, in kappaopioid receptor, and Lys303, in mu-opioid receptor using norBNI (13) and GNTI (14).84
Kiκ (nM)

Kiκ [E297K] (nM)

Kiμ (nM)

Kiμ [K303E] (nM)

13

0.12

12.5

101.9

0.77

14

0.75

12.9

9.23

0.06

This successful application of “message-address” concept in the design and
development of kappa-opioid receptor selective antagonists gives an insight in the
development of mu-opioid receptor selective antagonists.

4.

Summary
The application of ligands with high selectivity for each type of the opioid

receptors is crucial for the understanding of the mechanism of opioid actions. There are
currently many mu-opioid receptor agonists available but morphine is still the most
commonly used agonist. Morphine acts at the mu-opioid receptor to produce analgesic
effects. However, it can cause other adverse effects including respiratory depression,
dependence, and addiction.38

Therefore, the development of mu-opioid receptor

antagonists is important in the maintenance treatment of opioid addiction.
Currently, only two mu-opioid receptor antagonists, naloxone and naltrexone, are
approved by the FDA for the treatment of adverse effects associated with opioid
agonists.38 However, both naloxone and naltrexone carry low selectivity to the muopioid receptor and may cause other adverse side effects due to their low selectivity.42,52

27
Other types of mu-opioid receptor antagonists have been developed including peptide
ones and irreversible non-peptidyl ones. However, peptides can undergo metabolism
easier than non-peptides and irreversible antagonists limit the use of the compounds since
they inactivate the receptor indefinitely.58,71
The development of a non-peptide, reversible mu-opioid receptor antagonists is
important for the treatment of dependence and addiction to opioid agonists. These drugs
seem to be more promising because they will have less interference with the normal
function of the delta- and kappa-opioid receptors. Such mu-opioid receptor selective
antagonists may also be useful in the characterization of the mu-opioid receptor structurefunction relationship.

III. Project Design
The project, the development of selective non-peptidyl mu-opioid receptor
antagonists, consists of four parts: molecular design, chemical synthesis, biological
evaluation, and molecular modeling study. The novel ligands will be designed based on
the identification of important pharmacophore elements in several known opioid agonists
and antagonists. Chemical synthesis will be conducted to prepare the designed ligands.
Next, in vitro pharmacology studies will be pursued in order to determine the affinity of
these compounds for three types of opioid receptors. Finally, molecular modeling studies
will be carried out in order to visualize the binding modes of the ligands in the mu-opioid
receptor.

1.

Molecular Design
Applying the “message-address” concept, a comparative conformational analysis

of several known mu-opioid receptor agonists and antagonists will be conducted to
identify major pharmacophore elements, followed by docking studies of these ligands in
a homology model of mu-opioid receptor to identify the unique amino acid residues in
the binding locus. To be noted, previous studies have shown that extracellular loops,
especially EL2 and EL3, may be involved in the determination of ligand selectivity
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for opioid receptors based on the relatively low sequence homology level in the EL
domains among the three opioid receptors.86

1.1

Comparative Conformational Analysis of Mu-Opioid Receptor Agonists and

Antagonists
The design of novel selective mu-opioid receptor antagonists will be based on a
comparative conformational study utilizing highly selective mu-opioid receptor agonists
such as fentanyl (15, Figure 12) and endomorphin 2 (16, Figure 12).
As shown in figure 12, the phenylethyl moiety in fentanyl is orientated the same
way as the tyrosine (Tyr) residue at the first position of endomorphin 2. This suggests
that it may be related to their agonist activity for the mu-opioid receptor and belongs to
the “message” component of the molecule.

The N-phenyl ring connected to the

propanamide group in fentanyl may overlap with the third amino acid residue,
phenylalanine (Phe), of endomorphin 2. This might be the “address” part of these
molecules to recognize the mu-opioid receptor (please refer to message-address concept
in the background on pages 20-23).
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Figure 12. Comparative conformational analysis of selective mu-opioid receptor agonists
and antagonists.
The conformational analysis of clocinnamox (7), an irreversible mu-opioid
receptor antagonist, shows a correlation with the above results.

The 17-

cyclopropylmethyl group in clocinnamox may be positioned similarly to the phenylethyl
moiety of fentanyl and belongs to the “message” component of the molecule. To be
noticed, many mu-opioid receptor antagonists including GNTI, naltrexone, nalorphine
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and clocinnamox carry similar size substitutions at the 17-position. This may help
explain why clocinnamox acts as an antagonist to the mu-opioid receptor while fentanyl
acts as an agonist. Therefore, the “message” component of these antagonists may be the
cyclopropylmethyl group. However, the p-chlorophenyl moiety at the 14-position of
clocinnamox may overlap with the N-phenyl ring of fentanyl, the “address” component of
the molecule. This suggests that agonists and antagonists may share similar “address”
components that confer their common selectivity to the mu-opioid receptor, while their
“message” components are different due to the opposite signal transductions.

1.2

Docking Studies in a Homology Model of the Mu-Opioid Receptor
The results of the comparative conformational study between fentanyl,

endomorphin 2, and clocinnamox will be verified using a homology model of the muopioid receptor. This model will be built based on the X-ray crystal structure of bovine
rhodopsin. Bovine rhodopsin, also a member of the GPCR superfamily, has a 30%
sequence identity compared to the opioid receptors.87 Although the sequence homology
level between opioid receptors and bovine rhodopsin are not very high, it is possible to
build a plausible homology model of the mu-opioid receptor based on rhodopsin’s X-ray
crystal structure.87
Previously, a homology model was built for the mu-opioid receptor based on a Xray crystal structure of the dark state bovine rhodopsin (Figure 13). The homology
model of the mu-opioid receptor was further optimized in a membrane-aqueous system.87
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The interactions between naltrexone and the homology model of the mu-opioid receptor
have been well characterized.16

Figure 13. Homology model of the mu-opioid receptor in a membrane-aqueous
interface.87
The comparative conformational analysis study has been verified using docking
studies where clocinnamox is docked into the binding pocket of the homology model of
the mu-opioid receptor.

We have noticed that there is significantly low sequence

homology in the EL2 and the EL3 in the three opioid receptors while these regions are
important in the recognition and binding of opioid ligands.16,87 Docking studies of
clocinnamox show that the 14-p-chlorophenyl moiety of clocinnamox (address part) is
located in an aromatic area of the binding pocket at EL2 and EL3 locus (Figure 14).
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Figure 14. Docking study of clocinnamox in the mu-opioid receptor homology model.

The 14-p-chlorophenyl moiety in clocinnamox is located in an aromatic binding
pocket of the mu-opioid receptor and is considered the “address” component of
clocinnamox. The amino acid residues Tyr210, Phe313, and Trp318, are not conserved
in the delta- and kappa-opioid receptors. Therefore, similar aromatic binding pockets
may not exist in the delta- and kappa-opioid receptors.

Trp318 in EL3 has been

determined, through site-directed mutagenesis studies and chimera opioid models, to be a
significant contributor to the selectivity of the mu-opioid receptor agonists and
antagonists.88
Therefore, the hypothesis for this study is that a mu-opioid receptor ligand
carrying an aromatic structural feature that may interact with EL3 of the receptor might
lead to its high selectivity to the mu-opioid receptor. Based on this hypothesis, a series of
new ligands that may satisfy the requirements of the mu-opioid receptor binding pocket
will be designed and synthesized to test their affinity towards the mu-, delta- and kappaopioid receptors.
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1.3

Design of Selective Mu-Opioid Receptor Antagonists
Based on the previous studies and analysis, a series of novel ligands as 14-O-

heterocylic substituted naltrexone derivatives are designed as mu-opioid receptor
selective antagonists (Figure 15).

The hetero-aromatic moieties include pyridine,

quinoline and isoquinoline, which are attached to 14-O-position of naltrexone by an ester
bond. The nitrogen atom in the hetero-aromatic moieties may act as hydrogen bond
acceptors towards the extracellular binding locus of the mu-opioid receptor, since certain
amino acid residues on EL2 and EL3, e.g. Tyr210 and Trp318, were found to be essential
for ligand recognition through site-directed mutagenesis studies.87 It is also important to
note that Trp318 is a significant contributor to the selectivity of the mu-opioid receptor
agonists and antagonists.87
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Figure 15. Designed 14-O-heterocyclic substituted derivatives of naltrexone.

A second series of selective mu-opioid receptor antagonists, 6-N-heterocyclic
substituted naltrexamines, were previously designed and synthesized in our laboratories
for a similar purpose (manuscript submitted to the Journal of Medicinal Chemistry).89
These antagonists contain a heterocylic moiety including pyridine, quinoline, and
isoquinoline, linked at the 6-position of naltrexone through an amide bond (Figure 16).
The ligands carrying either the α- or β-configuration have been chemically synthesized to
determine if stereochemical arrangement plays an important role in the affinity and
selectivity for the mu-opioid receptor.
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The aromatic character of the heterocyclic moiety helps to provide an aromatic
interaction to the aromatic binding pocket in the mu-opioid receptor. The nitrogen atom
may act as a hydrogen bond acceptor to probe possible formations of hydrogen bonds
with the amino acid residue Trp318 of EL3 of the mu-opioid receptor.

Also, the

stereochemical arrangement may play a very important role for the affinity, as well as the
selectivity, of the ligand, based on previous compounds such as α-FNA and β-FNA.90
Although β-FNA binds to the mu-opioid receptor irreversibly, its epimer α-FNA does not
bind to the mu-opioid receptor irreversibly. However, α-FNA can protect against β-FNA
induced irreversible antagonism.91 This suggests that both α- and β-FNA interact with
the same site in the mu-opioid receptor but only β-FNA properly aligns and binds in the
mu-opioid receptor.90
Both sets of compounds, 14-O-heterocyclic substituted naltrexone and 6-Nheterocyclic substituted naltrexamine, have a phenyl and naphthalenyl compound
designed to act as controls in order to test the hydrogen bonding hypothesis.
Both series of compounds have been designed to test the hypothesis that the
addition of a heteroaromatic moiety to the backbone of naltrexone and naltrexamine may
allow for the formation of a hydrogen bonding interaction with Trp318 in EL3 of the
binding pocket of the mu-opioid receptor. This additional interaction may allow for the
creation of more selective mu-opioid antagonists.
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2.

Chemical Synthesis
Chemical synthesis of the 14-O-heterocyclic substituted naltrexone derivatives

will be conducted using synthetic pathways adapted from literature.92,93

The basic

scheme consists of the direct coupling of the heterocyclic moiety to the 3- and 14position of naltrexone. This is followed by the selective removal of the heterocyclic
moiety at the 3-position of naltrexone (Scheme 1).
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Cl
HO
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R
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Scheme 1. The synthetic route of 14-O-heterocyclic substituted naltrexone derivatives.
The heterocyclic moieties are represented by “R”. Reagents and conditions: a. DMF,
TEA, N2(g); b. 4% H2SO4 (aq), MeOH, NH4OH.
3.

O
O

Biological Evaluation of the 6-N-Heterocyclic Substituted Naltrexamine and

14-O- Heterocyclic Substituted Naltrexone Derivatives
Following the synthesis of the two series of naltrexone derivatives, bioassays will
be conducted to study the selectivity of these ligands for the opioid receptors. Monocloned opioid receptor expressed CHO and HEK293 cells will be utilized to conduct
these assays. The affinities of the ligands will be determined by conducting binding
assays utilizing tritiated radioligands, [3H]DAMGO, [3H]NTI and [3H]Nor-BNI, for the
mu-, delta-, and kappa-opioid receptors, respectively. Functional assays, i.e. [35S]GTPγS

O
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binding assay, will be applied to the naltrexone derivatives with at least 10-fold
selectivity for mu- over delta- and kappa-opioid receptors to determine whether the
compounds act as full agonists, partial agonists or antagonists. Ideally, a lead compound
will be identified as a mu-opioid receptor antagonist with high selectivity for the muopioid receptor over delta- and kappa-opioid receptors.

4.

Molecular Modeling Study
A homology model of the mu-opioid receptor will be adapted to illustrate the

possible docking modes of the 14-O-heterocyclic substituted naltrexone derivatives in the
mu-opioid receptor. The mu-opioid receptor homology model will be reconstructed and
revisited by the author of the thesis based on the X-ray crystal structure of the dark state
bovine rhodopsin.94 Site-directed mutagenesis data and chimera opioid receptor data will
be used to identify important amino acid residues in the binding pocket. The 14-Oheterocyclic substituted naltrexone derivatives will be docked into the hypothetical
binding pocket using GOLD to visualize the interactions of the ligands with the muopioid receptor.

The GOLD scores from the docking studies of these naltrexone

derivatives will be analyzed together with the binding affinities obtained from the
biological studies.
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5.

Summary of the Project Design
In summary, a series of novel opioid ligands as 14-O-heterocyclic substituted

naltrexone derivatives, will be designed based on molecular modeling studies on known
mu-opioid receptor selective agonists and antagonists. These naltrexone derivatives will
contain heteroaromatic moieties including pyridine, quinoline, and isoquinoline moieties
at the 14-O-position of naltrexone that may form a hydrogen bonding interaction with an
aromatic binding locus in EL domain of the mu-opioid receptor. Next, compounds in this
series, will be synthesized and the affinities will be determined for all three opioid
receptors using in vitro biological assays. Finally, a homology model of the mu-opioid
receptor will be built based on the X-ray crystal structure of the dark state bovine
rhodopsin. Docking studies of the 14-O-heterocyclic substituted naltrexone derivatives
will be conducted in order to visualize the interactions between the mu-opioid receptor
and these ligands.
In conclusion, the purpose of this study is the molecular design, chemical
synthesis, biological evaluation and molecular modeling study of selective non-peptidyl
mu-opioid receptor antagonists. This project may lead to the development of more
selective mu-opioid receptor antagonists with reduced adverse effects seen with other
opioid antagonists like naltrexone and naloxone.

IV. Results and Discussion

1.

Chemical Synthesis of 14-O-Heterocylic Substituted Naltrexone Derivatives

1.1

Chemical Synthesis Routes
Depending on commercially availability of the precursors of the 14-O-

heterocyclic moiety of naltrexone, one of the two synthetic routes is adapted from
literature to synthesize the 14-O-heterocyclic substituted naltrexone derivatives.92,93 The
first synthetic pathway involves the direct coupling reaction of an acyl chloride with
naltrexone (Scheme 2A), while the second involves the in situ conversion of a carboxylic
acid to an acyl chloride prior to the coupling reaction (Scheme 2B).
The heterocyclic moiety is first added to both the 3- and 14-positions of
naltrexone,

17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one,

to

generate the di-substituted naltrexone intermediate (Scheme 2). The following step
involves the chemoselective removal of the heterocyclic moiety at the 3-position. After
the purification of the naltrexone derivatives by column chromatography, the target
products are converted into hydrochloride salts. The final yields of these compounds
vary between 10 and 70% (Table 6).
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Scheme 2. The synthetic route for the 14-O-heterocyclic substituted naltrexone
derivatives.
A. The direct coupling of an acyl chloride heterocyclic moiety with naltrexone.
B. The conversion of a carboxylic acid heterocyclic moiety to an acyl chloride moiety, in
situ followed by coupling with naltrexone.
Reagents and conditions: a. DMF, TEA, N2 (g), 100 ºC, 4 h; b. 4% H2SO4 (aq), MeOH,
rt, 4h;
c. NH4OH, pH 7; d. SOCl2 ex., N2 (g), 80 ºC, 3 h; e. toluene, in situ; f. 2, DMF; g. H+; h.
pH 7.
The next step is the same for both routes A and B for all of the compounds. The
acyl chloride, commercially available or prepared in situ, is heated at reflux with
naltrexone and TEA in DMF (solvent) for up to 4 h at 100 °C under nitrogen atmosphere.
The solvent is then removed and the residue is dissolved in methanol and a 4% H2SO4
aqueous solution, to selectively remove the heterocyclic moiety attached to the 3-position
of naltrexone skeleton. This step of the reaction took up to 4 h at room temperature. A
weak base (NH4OH) is then applied to neutralize the mixture. The solvent is then
removed and column chromatography is conducted to separate out the final product. The
yields for these compounds vary (Table 6).
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Table 6. Percent yield of 14-O-heterocyclic substituted naltrexone derivatives.
Compound

14-O-heterocyclic
Substituent

Route

Percent Yield
(%)

B

50

A

69

A

24

A

10

A

24

22

A

17

23

B

22

A

7

17
N

18

N

19
N

20
21

N
N

N

24

1.2

The Synthesis of Acyl Chloride
In route B, the conversion of a carboxylic acid to an acyl chloride is necessary

because acyl chlorides are good electrophiles, and therefore very reactive. Both the
oxygen and chlorine on the carbonyl carbon of the acyl chloride are strong electron
withdrawing groups, allowing the carbonyl carbon to carry partial positive charge. This
will allow a weak nucleophile to attack the carbonyl carbon atom. The hydroxyl group
on carboxylic acids are not very good leaving groups and do not react in nucleophilic
substitution reactions except when the hydroxyl group is protonated to give water, a good
leaving group.94 To prevent protonation of the carboxylic acid, the environment is made
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basic with the use of triethylamine (TEA), which contains a tertiary amine that can
neutralize hydrochloric acid generated from the reaction through the formation of the salt
triethylamine hydrochloride.92,93
The conversion reaction in step d in scheme 2 involves heating at reflux the
carboxylic acid with thionyl chloride (SOCl2) under a nitrogen atmosphere.95 All the
components are pre-dried in order to ensure the reaction was free of water. The reaction
mixture is heated with an excess amount of SOCl2 at 80 °C for about 3 h.96 Then, toulene
is added and distilled in order to remove any excess of SOCl2.92,93

1.3

Chemoselective Deprotection of 3-O-Substitution
The addition of the heterocylic moiety to the skeleton of naltrexone is a “one-pot”

reaction. Therefore, both the 3- and 14-positions contain the heterocyclic moiety after
the direct coupling reaction of the substituent with naltrexone. A mildly acidic solution
(dilute H2SO4 solution) is used to selectively cleave the substituent at the 3-position but
still maintain the substitution on the 14-position of the naltrexone skeleton. The phenyl
ester moiety on the 3-position is highly unstable in acidic and in basic conditions, and can
be readily cleaved.97 However, the substituent at the 14-position is only stable under
mild acidic conditions and very labile in basic conditions. This is due to the 14-position
being a tertiary ester and is very unstable to basic hydrolysis.
Substitution on both the 3- and 14-positions requires a 2:1 ratio of acyl chloride
substituent to naltrexone.

This is due to the 3-position of naltrexone having more

accessibility to the substitution compared to the 14-position. The 14-position contains a
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tertiary alcohol and is also hindered by the methylcyclopropyl group. Therefore, the 3position is substituted first followed by the 14-position.

1.4

Methods for the Synthesis and Deprotection of Compounds 17, 20 and 24
Although most of the compounds are synthesized in the above manner, some

difficulty is encountered in the synthesis of compounds 17, 20 and 24. The synthesis of
compound 17 involves the conversion of picolinic acid to an acyl chloride. The first few
attempts produced a thick black residue and the reaction mixture probably is degraded.
Therefore, conversion of the carboxylic acid to an acyl chloride is ran overnight followed
by heating at reflux with naltrexone under a nitrogen gas atmosphere. Instead of adding
the dilute acid to cleave the substitution on the 3-position of naltrexone, column
chromatography is used to separate out the target compound. The final compound is
isolated as a dark brown residue and not a powder like most of the other 14-Oheterocyclic substituted naltrexone derivatives.
Compounds 20 and 24 are the control compounds. Problems are found in the
deprotection step. After these two compounds are heated at reflux with naltrexone, a disubstituted product was formed and there was difficulty in the removal of the
heterocyclic moiety at the 3-position. This may be due to the overall stability of the
compound. Several different attempts have been made to try to remove the heterocyclic
moiety at the 3-position (Table 7).
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Table 7. Deprotection conditions used to prepare compounds 20 and 24.
Attempt

Condition
Dilute acid (H2SO4)

1
2

3

4

5

Titration of sample from
attempt 1 from pH 4 to 1 with
addition of 1N H2SO4
Heat mixture to 50 °C under
nitrogen protection
Addition of 5 mg sodium
bicarbonate and dissolved in
THF
Dissolve in THF and potassium
carbonate at room temperature

Reaction Time

Overall Results

24 hours

Di-substituted product

Overnight

Di-substituted product

Overnight

Di-substituted product

Overnight

Di-substituted product

Overnight

Final mono-substituted
product

Attempts 1 to 4 (Table 7) did not accomplish the removal of the substituent at the
3-position. However, the final attempt was successful. Basically, THF and potassium
carbonate mixture is separated into two layers: K2CO3 saturated water layer and THF
layer.

The compound is isolated from the water layer and purified using column

chromatography.
All the compounds are converted into dihydrochloride salts and completely dried
using the vacuum pump prior to characterization by nuclear magnetic resonance (NMR),
infrared spectroscopy (IR), mass spectrometry (MS) and melting point determination.
All the compounds are evaluated for their affinity to all three opioid receptors through
radiolabeled competition binding assays, and their efficacy for the mu-opioid receptor
through [35S] GTPγS binding assay.
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1.5

Verification of Dihydrochloride Salts
After the synthesis of the 14-O-heterocylic substituted naltrexone derivatives,

they are converted into dihydrochloride salts through the addition of 2.2 equivalents of
1.25 M hydrochloric acid in methanol. However, the control compounds 20 and 24 are
converted to mono-hydrochloride salts. In order to verify whether these compounds are
in the mono- or dihydrochloride salt form, 1H-NMRs are taken for both the free base and
salt form of each compound. If the compound is a di-hydrochloric salt, then there should
be a difference in the chemical shifts between the free base and salt form in the
heterocyclic substituent of the compounds. For each compound, the differences between
the chemical shifts in the free base versus the salt form of the heterocylic substituent are
observed (Table 8 and Table 9). The chemical shifts of the heterocyclic substituent in
the salt form are shifted down field compared to the free base form. There is no major
difference in the chemical shifts of the salt form and free base form of the two control
compounds 20 and 24.
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Table 8. The difference of the chemical shifts between the salt and free base forms of the
first series of 14-O-heterocyclic substituted naltrexone derivatives.

O

N
O

R

O

HO

Compound

17

O

18

19

20

Substituent (R)

Positions:
2

-

0.34

0.07

0.00

3

0.90

0.72

-

0.12

4

0.60

-

0.69

0.11

5

0.91

0.72

0.76

0.12

6

0.36

0.34

0.42

0.00

* The change in the chemical shifts of the salt and free base was determined by δsalt-δfree
base.
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Table 9. The difference of the chemical shifts between the salt and free base forms of the
second series of 14-O-heterocyclic substituted naltrexone derivatives.

N

O
O
R

HO

Compound

21

O

O

22

23

24

Substituent (R)

Positions:
1

0.14

N

N

0.16

2

N

-

0.03

-

3

-

0.86

-

0.10

4

0.04

0.89

0.51

0.11

5

0.12

0.95

0.40

0.19

6

0.12

1.16

0.26

0.19

7

0.12

1.29

0.49

0.10

8

0.19

1.12

0.17

0.10

* The change in the chemical shifts of the salt and free base was determined by δsalt-δfree
base.
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All the compounds show a difference greater than 0.30 ppm in the chemical shifts
between the salt and free base form except for compound 21. Therefore, according to the
data it can be assumed that all compounds are dihydrochloride salts except that
compound 21 and the controls 20 and 24 are mono hydrochloride salts.
It has been reported that environmental change can cause the complete
conformational conversion of an amide skeleton upon the addition of acid.98 An Nmethyl amide containing N- 2,6-pyridinedicarboxamide moieties (43) that can switch its
conformation depending upon the acceptor ability of the solvent. With the addition of
trifluoroacetic acid (TFA) to the amides, a lower field shift in the aromatic protons can be
observed (Figure 17). The addition of TFA to compound 43 causes the nitrogen atom in
the pyridine ring to lie in the syn position with respect to the carbonyl group due to
hydrogen bond formantion.98
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Figure 17. Difference in
moieties with the addition of
determined by δ44-δ43.

N

H3C

43

Proton Assignment

O

O

43

44

Difference in
chemical shifts

7.60
7.60
0.00
7.73
8.43
0.70
7.24
8.04
0.80
7.31
7.91
0.60
proton chemical shifts for N-2,6-pyridinedicarboxamide
TFA (150 equiv).98 The difference in chemical shifts was

Mass spectrometry was also conducted for all of the compounds. The major peak
was found to be the mono-protonated 14-O-heterocyclic substituted naltrexone
derivatives. The second major peak was determined to be mono-protonated naltrexone
conjugated with the chloride ion. For some of the compounds the di-protonated product
can be seen but the relative intensity was low.

2.

Pharmacological Studies of 14-O-Heterocyclic Substituted Naltrexone
Derivatives
In order to determine the affinities of these newly synthesized derivatives of

naltrexone, several different radiolabeled binding assays were conducted.

First, a
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saturation binding assay was used to determine the affinity of the radioligand used for
each receptor and the approximate amount of receptors in the different monoclonal
receptor expressed cell lines. This was followed by competition binding assays to all
three opioid receptors to determine the 14-O-heterocyclic substituted naltrexone
derivatives’ affinity and selectivity. Finally, the compounds underwent a functional
assay to determine their potential agonist activity.

2.1

Cell Culture of Cell Lines Over-expressing Opioid Receptors
Before any of the compounds were evaluated in the different binding assays, cell

lines expressing the three opioid receptors were cultured and harvested for use in the
assays. For the mu- and kappa-opioid receptors, CHO cell lines were used. For the
delta-opioid receptor several different cell lines were used including HEK293, CHO and
NG108-15 cell lines. The CHO cell lines were cultured in DMEM/F12 media containing
5% fetal bovine serum (FBS), 0.2 mg/mL geneticin (G418) and 1% penicillinstreptomycin except 10% FBS was used for the DORCHO cell lines. The HEK cell lines
were cultured in DMEM media with 8% FBS, 0.2mg/mL G418, 1% penicillinstreptomycin, and 1.5 mM HEPES. The NG108-15 cell lines used DMEM media with
10% FBS, 1% penicillin-streptomycin, 0.2 mg/mL G418 and 100x HAT.99,100

2.2

Saturation or Scatchard Radiolabeled Binding Assay
In order to characterize the receptors, a saturation or scatchard binding assay was

used to determine the Bmax of the receptors for each cell line and Kd for the radiolabeled
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ligands for their respective receptors. Bmax is the maximum number of binding sites that
can be bound by the radioligand and is a measure of receptor density in the tissue
reported in pmol/mg.101 Kd is the affinity of the radioligand for the particular receptor
and is the concentration of radioactive ligand required to occupy 50% of the receptors.
Kd is reported in molar concentration units, in this case all of the Kd values were
reported in nanomolar concentration units. The saturation assay was performed for the
CHO cell lines expressing the delta-opioid receptor (DORCHO) and the kappa-opioid
receptor (KORCHO), and HEK cell lines expressing the delta-opioid receptor
(DORHEK) all from the University of Minnesota. For all the other cells lines, NG108-15
(delta-opioid

receptor)

and

mu-opioid

receptor

(MORCHO)

from

Virginia

Commonwealth University (VCU) and delta-opioid receptor (DORCHO) from Temple
University, the Bmax had already determined and used without further testing (Table
10).
The radioligands used in all the assays are highly selective for their corresponding
receptors.102 For the mu-, delta- or kappa-opioid receptors [3H] NLX, [3H] NTI or [3H]
Nor-BNI were used respectively. The saturation assay involves the competition of the
radiolabeled ligand at different concentrations with the same drug, except it is unlabeled
(cold), in excess for the corresponding receptors. However, the cold drug used for the
mu-opioid receptor was naltrexone.
Naltrexone can be used as the cold ligand instead of naloxone because naltrexone
has about 10-fold higher affinity for the mu-opioid receptor compared to naloxone.42,51
The cold ligand used to determine the non-specific binding needs to have high affinity for
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its receptor. Also, naltrexone and naloxone have comparable affinity to all three opioid
receptors.42,51
Table 10. Bmax and Kd for the different mono-cloned opioid expressed cell lines
determined by saturation binding assay.
Cell Line

Bmax
Kd
(pmol/mg) (nM)
MORCHO
3.00
2.00
DORCHO (Temple)
5.80
*
DORCHO (Minnesota)
1.21
0.46
DORHEK
1.51
0.36
KORCHO
3.37
0.65
* Saturation assay was not completed for the DORCHO cells from Temple University.
The Bmax was already determined and the Kd was assumed to be similar to the other
cells that express the delta-opioid receptor.
2.3

Competition Binding Assay
The competition binding assays were conducted for all the three opioid receptors

in order to determine the binding affinities for naltrexone and the naltrexone derivatives.
From this assay, IC50 values were determined and converted to Ki values using the
Cheng-Prusoff equation.103 The same radioligands and cold drugs from the saturation
binding assays were used in this assay. However, this time the concentration of the
naltrexone derivatives were varied, while the radioligand concentration was between 1 to
2 times their Kd values.

A.

Mu-Opioid Receptor
The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the

mu-opioid receptor was determined using [3H]NLX as the radioligand (2 nM) to compete
with the naltrexone derivatives. The non-specific binding was determined by an excess
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of cold naltrexone at a concentration of 10 μM. The MORCHO (from Dr. Selley’s
laboratory at VCU) cells were used to determine the affinity of the naltrexone derivatives
to the mu-opioid receptor. About 10 to 15 μg of protein was added to each tube. A
Bradford protein determination assay was used to determine and adjust the concentration
of protein required for the assay.104 The total volume of this assay was 500 μL. The
incubation time for this assay was 120 minutes in a 37 °C water bath.

Various

concentrations of the naltrexone derivatives were tested to determine their Ki values.
After incubation, the reaction was quenched with cold tris buffer. A Brandel harvester
was used to separate the bound from the free radioligand. The results were determined
utilizing a scintillation counter. Ki values are the result of triplicate determinations.

B.

Delta-Opioid Receptor
The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the

delta-opioid receptor was determined using [3H]NTI as the radioligand (0.5 nM) to
compete with the naltrexone derivatives. The non-specific binding was determined by an
excess of cold naltrindole (NTI) at a concentration of 10 μM. Although several different
cell lines were utilized in this assay, only the DORCHO (from Temple University) cells
were used to determine the ligands affinity. About 10 to 20 μg of protein was added to
each tube. A Bradford protein determination assay was used to determine and adjust the
concentration of protein required for the assay.104 The total volume of this assay was
1000 μL. The incubation time for this assay was 120 minutes in a 37 °C water bath.
Various concentrations of the naltrexone derivatives were tested to determine their Ki
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values. After incubation, the reaction was quenched with cold tris buffer. A Brandel
harvester was used to separate the bound from the free radioligand. The results were
determined utilizing a scintillation counter.

Ki values are the result of duplicate

determinations.

C.

Kappa-Opioid Receptor
The selectivity of the 14-O-heterocyclic substituted naltrexone derivative for the

kappa-opioid receptor was determined using [3H]Nor-BNI as the radioligand at a
concentration of 0.6 to 1.2 nM, about 1 to 2 times the Kd value determined in the
saturation assay. The non-specific binding was determined by an excess of cold nor-BNI
at a concentration of 10 μM. The KORCHO cells were used and about 20 to 30 μg of
protein was added to each tube. A Bradford protein determination assay was used to
determine and adjust the concentration of protein required for the assay.104

The

incubation time for this assay was 120 minutes in a 37 °C water bath. The total volume
of this assay was 500 μL. Various concentrations of the naltrexone derivatives were
tested to determine their Ki value. After incubation, the reaction was quenched with cold
tris buffer. A Brandel harvester was used to separate the bound from the free radioligand.
The results were determined utilizing a scintillation counter. Ki values are the result of
triplicate determinations.
There were a couple problems in the assay dealing with the radioligand.
[3H]Nor-BNI is very unstable and was kept cold in the presence of nitrogen gas. Also,
the [3H]Nor-BNI was dissolved in 5:2 toulene:ethanol.

Toulene at very high

105

concentrations can disrupt cellular membranes.
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Therefore, the toluene:ethanol solvent

was removed from the radioligand under vacuum pressure in an ice water bath for about
8 to 10 h. After the radioligand was completely dry, it was re-dissolved in ethanol. Also
a small amount of cold nor-BNI was added in order to dilute the concentration of
[3H]Nor-BNI to a lower specific activity since it is very unstable at a high specific
activity. Nitrogen gas was added to the [3H]Nor-BNI in ethanol to help prevent further
degradation. This process was conducted for small batches of [3H]Nor-BNI, about 100 to
150 μL, at a time.
Another problem seen in the assay was that the total amount of radioligand bound
was between 15 to 20% of the total amount of radioligand added (standards). In order to
compensate for this problem, the total volume was increased from 0.5 to 1 mL and the
amount of [3H]Nor-BNI was doubled from 0.6 to 1.2 nM, 2 times the Kd value. This
helps reduce the radioligand bound to between 7 to 8%.

3.

[35S]GTPγS Functional Binding Assay for the Mu-Opioid Receptor
A functional assay was used to compare the agonist activity of the naltrexone

derivatives to the mu-opioid receptor compared to DAMGO, a full mu-opioid receptor
agonist. From this assay, the potency, EC50, and the intrinsic efficacy, Emax, can be
determined. The EC50 is the molar concentration of an agonist to produce 50% of the
maximal possible effect. The Emax is the maximum effect of the agonist.106 DAMGO
has an Emax value of 366% stimulation of receptor and represents 100% agonist activity.
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All the naltrexone derivatives were compared to DAMGO’s Emax value in order to
determine whether these compounds are agonists, partial agonists, and antagonists.
The agonist activity of the naltrexone derivatives for the mu-opioid receptor was
determined using [35S]GTPγS as the radioligand.

[35S]GTPγS was diluted so the final

DPM count is about 125,000. The non-specific binding was determined using an excess
of cold gamma-GTP at a concentration of 20 μM. GDP was also added to all the tubes at
a concentration of 10 μM in order to obtain optimal agonist-stimulated binding. The
MORCHO cells were used and the approximate amount of protein added to each tube is
between 9 to 10 μg in the assay. A Bradford protein determination assay was used to
determine and adjust the concentration of protein required for the assay.104 Finally, TME
buffer with Na+ was utilized to improve agonist stimulated binding.107 The incubation
time for this assay was 90 minutes in a 37 °C water bath. The concentration of the
naltrexone derivatives tested was between 0.0001 nM to 10,000 nM.

4.

Competition Binding Assay Results for 14-O-Heterocyclic Substituted
Naltrexone Derivatives

4.1

14-O-Pyridinyl Substituted Naltrexone Derivatives
The results for the first set of compounds, 14-O-pyridinyl substituted naltrexone

derivatives, show that all of the compounds have nanomolar and subnanomolar affinity
for the mu-opioid receptor. More importantly, the first set of naltrexone derivatives
display higher selectivity for the mu-opioid receptor over the kappa- and delta-opioid
receptors (Table 11).
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Table 11. Binding assay results for the 14-O-pyridinyl substituted naltrexone derivatives.
Cmpd

R

δKi
(nM)
+/SEM
117.058 +/- 8.945

κKi
(nM)
+/SEM
5.150 +/- 0.264

Ratio
δ/μ

Ratio
κ/μ

Naltrexone

μKi
(nM)
+/SEM
0.260 +/- 0.017

Comparison of
Agonist Percent
Stimulation to
DAMGO

450

8

17

0.14 +/- 0.03

4610+/- 821

255 +/- 64.8

33650

1859

0.00

5.58 +/- 1.34

1144+/- 99.7

775 +/- 256

205

139

0.00

1.59 +/- 0.61

1310 +/- 306

565+/- 109

55

355

0.00

123+/- 38.2

>10,000

729+/- 144

>81

6

0.00

N

18

N

19
N

20

The Ki values for the mu- and kappa-opioid receptors are n=3 and the Ki value for the delta-opioid receptor is n=2. The
averages are reported along with their standard error of the means (SEM) for each compound. The comparison to percent
stimulation of DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional
assay. Note the abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean.
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Based on the results, compound 17 was determined to be the lead compound for
the first series of 14-O-pyridinyl substituted naltrexone derivatives. Compound 17 has
the highest affinity and selectivity for mu-opioid receptor compared to the other
derivatives in the first series of 14-O-pyridinyl substituted naltrexone derivatives (Figure
18). Compared to naltrexone, 17 has comparable affinity to the mu-opioid receptor, but
much higher selectivity for the mu-opioid receptor over the kappa- and delta-opioid
receptors. Compared to the control compound 20, it is clear that the nitrogen is necessary
for higher binding affinity to the mu-opioid receptor. Also, the GTPγS functional assay
showed no agonist activity for the mu-opioid receptor for up to 10,000 nM of compound
17.
Lead Compound 17 of the 14-O -pyridinyl Naltrexone:
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
Mu-opioid receptor

125

Delta-opioid receptor
Kappa-opioid receptor

Percent Stimulation
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5

Log Concentration of Compound 17

Figure 18. Competition binding curve for lead compound 17 for the mu-, delta-, and
kappa-opioid receptors.
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Compound 18 displays high selectivity for the mu-opioid receptor over the deltaand kappa-opioid receptors. When compared to naltrexone, 18 has one-tenth the affinity
of naltrexone but is much more selective for mu- over kappa-opioid receptors. Compared
to the lead compound 17, 18 shows lower selectivity to the mu-opioid receptor. Also, the
GTPγS functional assay shows no agonist activity for the mu-opioid receptor for up to
10,000 nM of compound 18.
Compound 19 shows a similar binding profile compared to compound 18. It has
high affinity and selectivity for the mu-opioid receptor compared to the delta- and kappaopioid receptors. However, it has about one-tenth the affinity to the mu-opioid receptor
compared to naltrexone and compound 17. Both compounds 18 and 19 have higher
affinity to the mu-opioid receptor compared to the control 20 suggesting that the nitrogen
may be playing an important role for binding to the mu-opioid receptor. Additionally, the
GTPγS functional assay shows negative results of the mu-opioid receptor for up to
10,000 nM of compound 19.
The control compound 20 displays very low affinity to the mu-opioid receptor
compared to naltrexone (about one-hundredth the affinity) and to the other compounds in
this series. Therefore, the nitrogen atom in compounds 17 to 19 seems to play an
important role in affinity and selectivity of these naltrexone derivatives to the mu-opioid
receptor.
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4.2

14-O-Quinolinyl and 14-O-Isoquinolinyl Substituted Naltrexone Derivatives
The results for the second set of 14-O-heterocyclic substituted naltrexone

compounds show that all of the compounds are more selective for the mu-opioid receptor
over the kappa- and delta-opioid receptors (Table 12). Also, these compounds have
nanomolar level affinity for the mu-opioid receptor.

63
Table 12. Binding assay results for the 14-O-quinolinyl and 14-O-isoquinolinyl substituted naltrexone derivatives.

Cmpd

R

μKi
(nM)
+/SEM

δKi
(nM)
+/SEM

κKi
(nM)
+/SEM

Ratio
δ/μ

Ratio
κ/μ

Comparison
of Agonist
Percent
Stimulation to
DAMGO

Naltrexone

0.260 +/- 0.017

117.058 +/- 8.945

5.150 +/- 0.264

450

8

21

68.40 +/- 6.04

> 10,000

>10,000

>146

>147

0.00

1.44 +/- 0.32

1362+/- 111

1377+/- 112

947

957

0.00

2.60 +/- 0.72

2824+/- 14.6

665 +/- 98.2

901

247

22.0 +/- 10.3

225 +/- 46.6

> 10,000

474 +/- 176

>44

2

0.00

N

22

N

23
N

24

The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for delta-opioid receptor is n=2. The averages
are reported along with their standard error of the mean (SEM) for each compound. The comparison to percent stimulation of
DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional assay. Note the
abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean.
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From the second series of naltrexone derivatives, 22 is determined to be the lead
compound. Compound 22 has lower affinity (about one-tenth) for the mu-opioid receptor
compared to naltrexone, however it has much higher selectivity for the mu-opioid
receptor over the kappa- and delta- opioid receptors. Naltrexone has comparable affinity
for the mu- and kappa-opioid receptors (Figure 19).

Compared to compound 24,

compound 22 also shows much higher affinity and selectivity to the mu-opioid receptor.
Therefore, the nitrogen plays an important role in the binding of these naltrexone
derivatives to the mu-opioid receptor. Additionally, compound 22 displayed no agonist
activity for up to 10,000 nM concentration in the GTPγS functional assay.
Lead Compound 22 of the 14-O -Quinolinyl Naltrexone:
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
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Figure 19. Competition binding curve for lead compound 22 for the mu-, delta-, and
kappa-opioid receptors.
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Compound 21 shows lower affinity to the mu-opioid receptor compared to
naltrexone. However, 21 still shows selectivity for the mu-opioid receptor over the deltaand kappa-opioid receptors.

Compared to the control 24, compound 21 has higher

selectivity for the mu-opioid receptor compared to the delta- and kappa-opioid receptors.
However, both compounds 21 and 24 display similar affinity to the mu-opioid receptor.
The addition of the two-ring system may be too bulky to fit well in the binding pocket of
the mu-opioid receptor, and this may explain the lower affinity seen with the quinoline
series compared to the pyridine series. Additionally, compound 21 displayed no agonist
activity for up to 10,000 nM concentration in the GTPγS functional assay.
Compound 23 shows lower affinity to the mu-opioid receptor compared to
naltrexone. However, 23 displays selectivity for the mu-opioid receptor over the deltaand kappa-opioid receptors. Compared to the lead compound 22, compound 23 shows
similar affinity to the mu-opioid receptor. Compared to the control 24, compound 23 has
higher selectivity and affinity for the mu-opioid receptor compared to the delta- and
kappa-opioid receptors. Additionally, compound 23 displayed no agonist activity for up
to 10,000 nM concentration in the GTPγS functional assay.
The control compound 24 shows low affinity to the mu-opioid receptor compared
to naltrexone and to the other compounds in this series. The nitrogen seems to play an
important role in affinity and selectivity of these naltrexone derivatives to the mu-opioid
receptor. The decrease in affinity may be due to the addition of the second ring. The
substitution may be too bulky and may not be situated properly into the binding pocket.
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4.3

Comparison between the Lead Compounds 17 and 22
Compound 17 and 22 are determined to be the lead compounds for the pyridinyl

and quinolinyl series of the 14-O-heterocylic substituted naltrexone derivatives. Both
compounds contain a nitrogen atom next to the ester linkage.

The nitrogens in

compounds 17 and 22 may arrange themselves in similar conformations in the binding
pocket of the mu-opioid receptor. Also, compound 17 has 10-times higher affinity for the
mu-opioid receptor compared to compound 22. This may be due to the addition of the
second ring, making compound 22 more bulky.
Further in vitro studies need to be conducted on these two lead compounds such
as a Schild regression analysis to determine their apparent affinities, or pA2, values for
the mu-opioid receptor.

The Schild regression is used to determine the nature of

antagonist either competitive or non-competitive. Schild regression is used to compare
the change in dose ratios, the ratio of the EC50 of an agonist alone compared to the EC50
in the presence of an antagonist. By altering the concentration of the antagonist, the dose
ratio is altered.108
Additionally, in vivo studies should be conducted to see how they act in the body
and what kind of effects they produce in the body. Finally, further optimization may be
conducted in order to explore the possibility of an amide linkage over the ester linkage to
the 14-position of naltrexone.
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5.

Molecular Modeling Study of the 14-O-Heterocyclic Substituted Naltrexone
Derivatives in the Mu-Opioid Receptor
Molecular modeling studies have been conducted on the 14-O-heterocyclic

substituted naltrexone derivatives, as well as naloxone and naltrexone, to gain insight on
the interactions of the compounds in the binding pocket of the mu-opioid receptor. A
homology model of the mu-opioid receptor was built based on the X-ray crystal structure
of the dark state of bovine rhodopsin (1U19; resolution of 2.2 Å).109 Clustal X was
applied to align the sequences of human mu-, delta- and kappa-opioid receptors with
bovine rhodopsin (Figure 20).110 Furthermore, the conserved residues found throughout
most of the GPCRs were used to identify the helical regions of the opioid receptors and
rhodopsin.109
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Figure 20. Sequence alignment of the human mu-, delta-, and kappa-opioid receptors to
bovine rhodopsin (1U19) using Clustal X. The boxes represent the transmembrane (TM)
regions. The * represents conserved amino acid residues found among all GPCRs.
Abbreviations: MOR=mu-opioid receptor, DOR=delta-opioid receptor, KOR=kappaopioid receptor, Bov. Rhodo=bovine rhodopsin.
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First, the N and C termini of the mu-opioid receptor were cleaved off before Ile68
and after Pro355 since the N and C termini have very low sequence homology among the
three opioid receptors and bovine rhodopsin. The helices of bovine rhodopsin were
directly mutated with the residues of mu-opioid receptor. Loop searches were conducted
for the gaps found in EL2, EL3 and IL3 in order to maintain the conformation of the
three-dimensional structure of the rhodopsin loops.

Since EL2 is important in the

interaction of the opioids in the binding pocket, maintaining the conformation and
integrity of EL2 was important.

Before minimization was conducted, side chain

placement with a rotamer library (SCWRL) was used to check and fix improper
positioning of the amino acid residues.111 The disulfide bond between cysteine residues
130 of TM3 and 180 of EL2 was rejoined, and hydrogens were added and lone pairs were
removed. The receptor was minimized with Gasteiger-Hückel charges with a dielectric
constant of 4.0 and 100,000 iterations.

Procheck was also performed to validate

acceptable phi and psi angles in the protein and all of the residues were found to be in
acceptable angle conformations.
Initial docking studies were conducted for the 14-O-heterocylic substituted
naltrexone derivatives using GOLD 3.1.112 A distance constraint was set at 4Å between
the positively charged nitrogen atom at the 17-position of naltrexone to the oxygen
O1278 of the amino acid residue Asp149 of the mu-opioid receptor. It turned out that the
binding pocket is not large enough to incorporate the bulky heterocyclic side chain at the
14-position of the naltrexone derivatives. In order to accommodate the larger naltrexone
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derivatives, compound 22 was interactively docked into the homology model of the muopioid receptor.
Based on site-directed mutagenesis data, compound 22 was positioned in a similar
manner as naltrexone. First, the positively charged amino group at the 17-position of the
compound was positioned between 3 to 4Å away from the amino acid residue Asp149
since it has been shown to form a hydrogen bond with one of the oxygens of Asp149.87
Next the phenol moiety at the 3-position of naltrexone and was placed about 3 to 4Å
apart from the aromatic amino acid residues, Tyr212 and Phe223, of EL2.87 The amino
acid residue Tyr150 of TM3 may also form a hydrogen bond with the phenol oxygen at
the 3-position of the naltrexone backbone.88

The final hydrophobic interaction is

between Leu221, Trp320 and Ile324 that can also interact with piperidinyl and
cyclohexanoyl in naltrexone backbone. Trp320 in EL3 was found to be critical in the
binding of mu-opioid receptor.11 When Trp320 was mutated to leucine and lysine, the
affinity of naltrexone significantly decreased in the mutated mu-opioid receptor.87,88
By satisfying these interactions, compound 22 was docked into the binding pocket
and the receptor-ligand complex was minimized. Compound 22 was used because it
showed satisfactory binding affinity and selectivity for the mu-opioid receptor. After the
minimization was complete, molecular dynamics simulation was conducted in Sybyl 7.1.
The dynamics simulation was done in order to allow the formation of a larger
binding pocket by moving amino acid residue side chains out of the binding pocket. The
dynamic simulations used Gasteiger-Hückel charges, a dielectric constant of 4.0, an
aggregate with a 10Å radius around the ligand and a distance constraint of 4Å between
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the positively charged amino group at the 17-position of naltrexone backbone to one of
the oxygens of the amino acid residue Asp149 of the receptor. Dynamic simulation
involves the heating of the receptor, allowing the movement of side chains and stretching
the binding cavity. After the dynamics simulation the homology model of the mu-opioid
receptor was minimized. The final binding cavity was analyzed and the compound was
removed (Figure 21).

Figure 21. Binding pocket of the mu-opioid receptor with the critical amino acid
residues.
The docking studies were conducted using GOLD 3.1 for each of the 14-Oheterocyclic substituted naltrexone derivative and two mu-opioid receptor antagonists,
naltrexone and naloxone, with the newly formed homology model of the mu-opioid
receptor.112 Default settings were used in GOLD with a distance radius set to 10Å where
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the central residues were set to oxygen O1278 of Asp149. Also, a distance constraint of
4Å was set between the 17-nitrogen atom of naltrexone with one of the oxygen O1278 of
Asp149.

The GOLD scores for naltrexone and naloxone are 54.71 and 53.88,

respectively. The GOLD scores for the 17 to 20 derivatives range from 68.39 to 82.20
and for the 21 to 24 derivatives range from 69.38 to 73.98. The gold scores for all of the
compounds are summarized in Table 13.

73
Table 13. Gold docking scores for opioid antagonists, naloxone and naltrexone, and 14-O-heterocyclic substituted naltrexone
docked into the binding cavity of the homology model of the mu-opioid receptor.51
Cmpd

R

Ki μ
(nM)

Gold
Score

S
(hb_ext)

S
(vdw_ext)

S
(hb_int)

S
(int)

S
(con)

Naltrexone

0.26

54.71

6.48

37.82

0.00

-3.77

-0.00

Naloxone

1.90

53.88

6.48

37.17

0.00

-3.69

-0.00

0.14

70.19

6.60

48.04

0.00

-2.47

-0.00

5.58

69.38

5.83

48.88

0.00

-3.67

-0.00

1.59

73.98

7.10

49.88

0.00

-1.70

-0.00

123

71.86

6.54

49.44

0.00

-2.66

-0.00

68.4

71.92

6.14

52.16

0.00

-5.93

-0.00

1.44

82.20

3.05

60.71

0.00

-4.33

-0.00

2.69

68.89

6.73

53.92

0.00

-10.97

-0.00

225

68.39

6.28

55.45

0.00

-14.14

-0.00

17
N

18

N

19
N

20
21

N
N

22
23
N

24

Abbreviations include Cmpd – Compound; R – substituent; S – Gold score component; hb – hydrogen bonding; vdw – Van der
Waals interactions; ext – external interactions, int – internal interactions. The score components for constraints indicates a
negative score depending on the ability of the docking solution to meet the defined constraints.
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The docking scores do not seem to correlate well with the actual binding data
obtained from the competition binding assays for the mu-opioid receptor. First, naloxone
and naltrexone are known opioid antagonist but are not selective for the mu-opioid
receptor. They both show similar selectivity for the mu- and kappa-opioid receptors.
Their GOLD scores are the lowest among all of the compounds docked into the
homology model of the mu-opioid receptor. This may be due to the homology model
being optimized with one of the 14-O-heterocyclic substituted naltrexone derivatives
aligned in its binding pocket.
From the first series, pyridinyl series of compounds (17 to 20), the GOLD scores
range from 69.38 to 73.98. This may be due to the binding pocket of the homology
model being explored around these naltrexone derivatives.

There is no significant

difference in the GOLD scores between all four ligands. However, there are some
significant differences seen in their affinities for the mu-opioid receptor shown in the in
vitro binding assays. Therefore, the homology model does not display an accurate
depiction of what is really occurring in the binding pocket. These homology models are
hypothetical pictures of how the compounds might bind.
From the second series, quinolinyl series of compounds (21 to 24), the GOLD
scores range from 68.39 to 82.20.

This may be due to the binding pocket of the

homology model being explored around these naltrexone derivatives. Also, compound
22 has the highest GOLD score of all the naltrexone derivatives showing that the binding
pocket of the homology model was optimized with this compound. Again, there is no
significant difference in the GOLD scores between all four ligands. But, there are some
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significant differences seen in their affinities for the mu-opioid receptor shown in the in
vitro binding assays. Therefore, the homology model does not display an accurate
depiction of what is really occurring in the binding pocket. These homology models are
hypothetical pictures of how the compounds might bind.
The docking solutions for several of these compounds including the two lead
compounds, 17 and 22, as well as naloxone and naltrexone are shown in figures 22 to 24.
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N
N

N

O
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HO
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Figure 22. Lead compound 17 best ranked docking solution in the binding cavity of the
mu-opioid receptor homology model.
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Figure 23. Compound 22, highest Gold score of all derivatives, best ranked docking
solution in the binding cavity of the mu-opioid receptor homology model.
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Figure 24. Opioid antagonists naltrexone (purple) and naloxone (yellow) best ranked
docking solutions in the binding cavity of the mu-opioid receptor homology model.
In the homology model of the mu-opioid receptor binding pocket, naloxone and
naltrexone seem to be overlapping each other (Figure 24).

Compared to the lead

compound, 17, of the 14-O-heterocyclic substituted naltrexone derivatives, naltrexone is
not interacting with the amino acid residue Trp320, which seems to interact with the
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pyridine substituent on the lead compound, 17 (Figure 25). This may help explain the
high Van der Waals contributions for the 14-O-heterocyclic substituted naltrexone
derivatives and the lower GOLD scores of naloxone and naltrexone. Also, the poor
correlation seen between the affinities of the 14-O-heterocylic substituted naltrexone
derivatives and the GOLD score values may be due to the small sample size.

Figure 25. Opioid antagonist naltrexone (purple) and lead compound 17 (green) best
ranked docking solutions in the binding cavity of the mu-opioid receptor homology
model.
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6.

Competition Binding Assay Results for the 6-N-heterocyclic Substituted

Naltrexamine Derivatives
Two different sets of 6-N-heterocyclic substituted naltrexamine derivatives were
designed (see Figure 16 on page 30). The first set carries a pyridinyl ring and the second
set carries a quinolinyl or isoquinolinyl ring. Also, the α and β configurations at the 6position of the naltrexone were investigated to determine if stereochemical arrangement
altered their affinities towards the mu-opioid receptor.
A hetero-aromatic moiety was introduced to the 6-position of naltrexamine in
order to design selective mu-opioid antagonists. An amide bond was used as the linkage
of the side chain moiety to the skeleton of naltrexamine. Both the α and β stereochemical
configurations of these compounds were synthesized to determine if stereochemical
arrangement plays an important role in affinity and selectivity for the mu-opioid receptor.
The nitrogen in the aromatic system acts as a hydrogen bond acceptor to probe the
possibility of hydrogen bond formation with amino acid residues Tyr210 or Trp318.
Control compounds with phenyl and naphthalene rings were also designed and
synthesized as control compounds to test the hydrogen bonding hypothesis.

6.1

6-N-Pyridinyl Substituted Naltrexamine Derivatives
The first set of compounds, 6-N-pyridinyl substituted naltrexamine derivatives, all

show nanomolar to subnanomolar affinity for the mu-opioid receptor (Table 14).
Stereochemical arrangements did not seem to be a major factor in the determination of
affinity and selectivity of these compounds for the mu-opioid receptor. The controls, 31
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and 32, display little selectivity between the mu- and kappa-opioid receptors. This
suggests that the nitrogen in the substitution may play an important role in the binding of
these naltrexamine derivatives.
From the pyridinyl series of compounds, compound 26 is determined to be a lead
compound (Figure 26). Compound 26 has similar binding affinity to the mu-opioid
receptor compared to naltrexone. However, 26 is much more selective to the mu-opioid
receptor compared with naltrexone. Compound 26 has higher selectivity to the muopioid receptor compared to the control compound 32. However, control compound 31
seems to have similar binding and selectivity characteristics as compound 26.
Additionally, the GTPγS functional assay was conducted and the Emax of compound 26
was compared with the Emax of DAMGO. From these results, it seems that compound
26 acts as a partial opioid antagonist to the mu-opioid receptor compared with DAMGO.
However, the control compound 31 also seems to act as a partial antagonist for the muopioid receptor, while compound 31 shows higher agonist activity compared with
compound 26.
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Lead Compound 26 of the 6-N -Pyridinyl Naltrexamine:
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
Mu-opioid receptor
125

Delta-opioid receptor
Kappa-opioid receptor

Percent Stimulation

100

75

50

25

0
-3

-2

-1

0

1

2

3

4

5

Log Concentration of Compound 26

Figure 26. Competition binding curve for lead compound 26 for the mu-, delta-, and
kappa-opioid receptors.
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Table 14. Binding assay results for the 6-N-pyridinyl substituted naltrexamine derivatives.
Cmpd

6Config.

6-N
R

Naltrexone
25
26

α
β

27

α

28

β

29

α

30

β

N

N

N

μKi
(nM)
+/SEM
0.260 +/- 0.017

δKi
(nM)
+/SEM
117.058 +/- 8.945

κKi
(nM)
+/SEM
5.150 +/- 0.264

Ratio
δ/μ

0.16 +/- 0.08
0.15 +/- 0.04

Ratio Comparison of Agonist
κ/μ
Percent Stimulation to
DAMGO

450

8

450 +/- 92.6
3667 +/- 34.8

85.2 +/- 24.8
5.98 +/- 1.30

2728
24779

517
40

44.82 +/- 4.50
29.11 +/- 5.00

0.59 +/- 0.11

2060 +/- 354

21.6 +/- 10.0

3515

37

37.32 +/- 4.87

0.41 +/- 0.08

3063 +/- 87.7

59.5 +/- 8.31

7398

144

22.72 +/- 0.84

2.79 +/- 0.44

678 +/- 168

234 +/- 12.6

243

84

37.79 +/- 2.68

6.46 +/- 1.56

2375 +/- 232

307 +/- 74.8

367

47

41.09 +/- 4.32

α
0.13 +/- 0.04
443 +/- 56.4
46.0 +/- 6.68
3464
359
41.24 +/- 7.48
31
(Control)
β
1.02 +/- 0.34
820 +/- 57.6
8.75 +/- 1.72
801
8
67.29 +/- 3.96
32
(Control)
The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for the delta-opioid receptor is n=2. The
averages are reported along with their standard error of the means (SEM) for each compound. The comparison to percent
stimulation of DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional
assay. Note the abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean; Config –
configuration.
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Another type of [ S]GTPγS functional assay was conducted to determine if these
35

compounds are antagonists and the amount of antagonism they produce. Therefore, an
assay was conducted to generate a dose-response curve of DAMGO, a mu-opioid
receptor agonist, with and without the naltrexamine derivatives.

An antagonist is

supposed to produce a right shift in the curve and the shift in the curve is measured to
demonstrate the relative antagonist activity of the compound.
To further characterize compound 26, a functional assay was conducted to
determine whether or not it displays antagonistic effects on the interaction of DAMGO
with the mu-opioid receptor. Compound 26 produces a right shift in the stimulation
curve produced by DAMGO activation of the receptor (Figure 27). The EC50 and Emax
for DAMGO alone is 68.3 nM and 424.66% stimulation, respectively. The addition of
7.5 nM of compound 26, about 30-times the IC50 (0.26 nM) of compound 26, alters the
EC50 and Emax for DAMGO to 118.0 nM and 408.48% stimulation, respectively. There
is a 2-fold increase in the EC50 and a slight almost negligible decrease in the stimulation
of [35S]GTPγS. The dissociation constant, or Ke, for compound 26 is 16.089 +/- 8.640
nM. The reported dissociation constant or Ke for naltrexone is 0.33 nM.113 In order to
make a better comparison with naltrexone, a pA2 value needs to be determined using a
Schild regression analysis with varying concentrations of antagonist. The pA2 value for
naltrexone is reported to be about 8.9 when given intravenously to rats given DAMGO.114

84

Lead Compound 26 of 6-N-Pyridinyl Substituted Naltrexamine:
35

[ S]GTPγS Agonist Binding Assay Effects on the Binding of DAMGO at the Mu-Opioid Receptor
DAMGO
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Figure 27. Stimulation of [35S]GTPγS by DAMGO and the effects of 26 on the
stimulation produced by DAMGO at the mu-opioid receptor. The concentration of 26
used in this assay is 7.5 nM. The averages of the data was produced from an n=2.

6.2

6-N-quinolinyl and 6-N-isoquinolinyl Substituted Naltrexamine Derivatives
The second set of compounds, 6-N-quinolinyl and 6-N-isoquinolinyl substituted

naltrexamine derivatives, subnanomolar to nanomolar affinity to the mu-opioid receptors
(Table 15). Stereochemical arrangements did not seem to be a major factor in the
determination of affinity and selectivity of these compounds for the mu-opioid receptor.
The control compound 42, displays no selectivity between all three opioid receptors,
while control compound 41 shows some selectivity to the mu-opioid receptor compared
to the delta- and kappa-opioid receptor. However, it also displays lower affinity to the
mu-opioid receptor compared to naltrexone and the other heterocyclic compounds in this
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series. The control compounds display a decrease in affinity to the mu-opioid receptor
and may suggest that the nitrogen in the substitution may play an important role in the
binding of these naltrexone derivatives.
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Table 15. Binding assay results for the 6-N-quinolinyl and 6-N-isoquinoline substituted naltrexamine derivatives.
Cmpd

Config.

6-N
R

Naltrexone

μKi
(nM)
+/SEM
0.260 +/- 0.017

δKi
(nM)
+/SEM
117.058 +/- 8.945

κKi
(nM)
+/SEM
5.150 +/- 0.264

0.23 +/- 0.12

2161+/- 125

Ratio Ratio
δ/μ
κ/μ

Comparison of Agonist
Percent Stimulation to
DAMGO

450

8

10.6 +/- 1.03

9398

46

40.9 +/- 7.20

33

α

34

β

0.10 +/- 0.03

186 +/- 2.58

5.14 +/- 1.33

1775

49

65.4 +/- 6.13

35

α

0.56 +/- 0.15

1108 +/- 103

26.9 +/- 5.32

1997

49

15.8 +/- 2.53

36

β

0.11 +/- 0.04

578 +/- 5.28

1.75 +/- 0.76

5349

16

33.0 +/- 2.46

37

α

0.13 +/- 0.03

360 +/- 11.3

2.00 +/- 0.12

2791

15

44.8 +/- 3.96

38

β

N

0.08 +/- 0.02

125 +/- 32.3

0.62 +/- 0.22

1527

8

53.4 +/- 8.74

39

α

N

0.71 +/- 0.27

338 +/- 54.2

6.84 +/- 2.62

473

10

75.7 +/- 17.8

40

β

N

0.14 +/- 0.04

352.8 +/- 10.6

1.29 +/- 0.23

2613

10

53.0 +/- 6.75

N

N

α
8.78 +/- 1.80
861 +/- 168
641 +/- 166
98
73
72.8 +/- 6.07
41
(Control)
β
57.4 +/- 0.26
30.2 +/- 4.80
67.3 +/- 17.8
0.52
1
11.9 +/- 0.69
42
(Control)
The Ki values for the mu- and kappa-opioid receptor are n=3 and the Ki value for delta-opioid receptor is n=2. The averages
are reported along with their standard error of the means (SEM) for each compound. The comparison to percent stimulation of
DAMGO is the Emax of the compound compared to the Emax of DAMGO using a [35S]GTPγS functional assay. Note the
abbreviations are Cmpd – compound; R – substituent; SEM - standard error of the mean; Config - configuration.
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From the second series of compounds, compound 35 is determined to be a lead
compound to undergo further optimization. Compound 35 has comparable affinity with
naltrexone to the mu-opioid receptor.

However, this compound displays higher

selectivity for the mu-opioid receptor over the delta- and kappa-opioid receptors not seen
with naltrexone (Figure 28). Compared to the control compounds 41 and 42, compound
35 displays both higher selectivity and affinity to the mu-opioid receptor suggesting that
the nitrogen may play an important role in its binding to the mu-opioid receptor. Also,
the GTPγS functional assay was conducted and the Emax value of compound 35 was
compared with the Emax of DAMGO. From these results, it seems that compound 35
acts as a partial opioid antagonist to the mu-opioid receptor compared with DAMGO.
However, the control compound 42 also seems to act as a partial antagonist for the muopioid receptor.
Lead Compound 35 of the 6-N -Isoquinoline Substituted Naltrexamine:
Competition Binding Assay for Mu-, Delta- and Kappa-Opioid Receptors
Mu-opioid receptor
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Figure 28. Competition binding curve for lead compound 35 for the mu-, delta-, and
kappa-opioid receptors.
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To further characterize compound 35, a functional assay was conducted to
determine whether or not it displays antagonistic effects on the interaction of DAMGO
with the mu-opioid receptor. Stimulation of [35S]GTPγS through binding of an agonist
produces a sigmoidal concentration effect curve. Compound 35 produced a right shift in
the stimulation of mu-opioid receptor by DAMGO (Figure 29). The EC50 and Emax for
DAMGO alone are 57.1 nM and 243.83% stimulation, respectively. The addition of 20.0
nM of naltrexamine derivative 35, about 20-times the IC50 (1.00 nM), altered the EC50
and Emax for DAMGO to 73.5 nM and 221.45% stimulation, respectively. A 1.2-fold
increase was seen in the EC50 and a slight almost negligible decrease in the stimulation of
[35S]GTPγS. The dissociation constant, or Ke, for compound 35 is 74.204 +/- 5.260 nM
and only a 1.2-fold shift increase was observed with a 20.0 nM concentration of
compound 35. A Schild regression analysis needs to be conducted where concentrationeffect curves are constructed in the presence of increasing concentrations of antagonist in
order to determine the apparent affinity, pA2, for compound 35.
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Lead Compound 35 of 6-N -Isoquinoline Substituted Naltrexamine:
35

[ S]GTPγS Agonist Binding Assay Effects on the Binding of DAMGO at the MuOpioid Receptor
DAMGO
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Figure 29. Stimulation of [35S]GTPγS by DAMGO and the effects of 35 on the
stimulation produced by DAMGO at the mu-opioid receptor. The concentration of 35
used in this assay is 20.0 nM. The averages of the data was produced from an n=2.
6.3

Comparison of the Lead Compounds 26 and 35
From the 6-N-heterocyclic substituted naltrexamine derivatives, two lead

compounds were identified: 26 and 35. In order to further characterize the antagonistic
profile of these two compounds, a Schild regression analysis needs to be conducted with
varying concentrations of the compounds in order to determine and compare their
apparent affinities, pA2 values. The two different configurations, α and β, shows no
difference in their affinities towards the mu-opioid receptors. This may be explained by
their three-dimensional structure between the α-configuration (33) and β-configuration
(34) of the 6-N-heterocyclic substituted naltrexamine derivatives (Figure 30). The lead
compounds can be further optimized by the addition of a third phenyl ring to compound
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35 in order to see if the increase in bulk is tolerated at this position. Compounds 39 and
40 have two nitrogen atoms in the quinoline ring and demonstrate partial agonist activity
around 52.95% and 75.69% for the α and β configurations, respectively. Therefore, the
addition of the second nitrogen atom showed no enhancement of affinity or antagonism.

Figure 30. Overlay of the three-dimensional configurations of compounds 33 (left) and
34 (right).

V. Conclusions
Currently there are many opioid agonists available for clinical use as analgesics
that act in the centeral nervous system through the opioid receptors. There are three main
opioid receptors, including the mu-, delta-, and kappa-opioid receptors. However, many
of these agonists have been associated with notorious side effects including respiratory
depression, tolerance and dependence. Morphine is the most commonly used opioid
agonist in the treatment of chronic and post-operation pain. However, morphine is highly
addictive both physically and psychologically.2 It has been shown that the analgesic and
adverse effects of morphine are due to its interactions with the mu-opioid receptor.
Therefore, the characterization of the mu-opioid receptor is essential for understanding
the addictive and analgesic actions of morphine.
The addiction and dependency of these opioid receptor agonists can be treated
through detoxification or drug replacement therapy, including the application of opioid
antagonists. Opioid antagonists also play important roles in the pharmacological study of
opioid receptors.

Due to the role of the mu-opioid receptor in analgesia and drug

addiction, a highly selective mu-opioid receptor antagonist will be useful as a
pharmacological tool in the study of the structure-activity relationships of mu-opioid
receptors.
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Naltrexone is a non-peptide mu-opioid receptor antagonist. It also is a long-acting
and reversible opioid ligand in the treatment of opioid dependence and many other
addictions.

Although naltrexone has the ability to promote abstinence and prevent

relapse, it also has many side effects due to its low selectivity to the opioid receptors.6,9
On the other hand, CTAP and CTOP, two representative mu-opioid receptor selective
peptidyl antagonists, are available but may undergo metabolic inactivation faster than the
non-peptidyl opioid antagonists. Therefore, the development of selective non-peptidyl
mu-opioid receptor antagonists is necessary to help alleviate any adverse effects seen by
opioid antagonists with low selectivity.
Besides the antagonists being selective for the mu-opioid receptor, these
compounds also need to be reversible. Irreversible antagonists will bind covalently to the
receptor and inactivate the receptor indefinetly.

Reversible antagonists would be

preferred since they temporarily “knock-out” the receptors during pharmacological
studies and can be washed out from the binding locus to revive the receptors.
This project involved the design of reversible and selective non-peptidyl muopioid receptor antagonists. Since naltrexone has high affinity to the mu-opioid receptor,
it is an ideal template for the development of these antagonists. The molecular design of
these antagonists was based on the identification of important pharmacophore elements
found in several known opioid agonists and antagonists. By applying the “messageaddress” concept and comparative conformational studies, the major pharmacophore
elements were identified in previous studies. From this study it was suggested that
agonists and antagonists may share a similar “address” component that confers their
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selectivity to the mu-opioid receptor while the “message” component is different due to
opposite signal transductions.
Site-directed mutagenisis and molecular modeling studies have shown that certain
amino acid residues are critical for ligand selectivity. Amino acid residues that comprise
an aromatic binding pocket include Tyr210, Phe313, and Trp318 located in extracellular
loops (EL) 2 and 3 are not conserved in the delta- and kappa-opioid receptors. Therefore,
similar aromatic binding pockets may not exisit in the delta- and kappa-opioid receptors.
More importantaly, Trp318 is a significant contributor to the selectivity of the mu-opioid
receptor agonists and antagonists.88
Based on previous studies conducted in Dr. Zhang’s laboratory, it was determined
that a mu-opioid receptor antagonist with an aromatic structural feature may interact with
EL3 and lead to higher selectivity to the mu-opioid receptor. Therefore, the specific
hypothesis for this study was that a mu-opioid receptor antagonist with an aromatic
structural feature may interact with EL3 and lead to higher selectivity to the mu-opioid
receptor. A series of new ligands that satisfy the requirements of the mu-opioid receptor
binding pocket were designed and synthesized to test their affinity towards the mu-,
delta- and kappa-opioid receptors.
Two novel series of selective non-peptidyl mu-opioid receptor antagonists were
developed. The first series are 14-O-heterocylic substituted naltrexone derivatives that
were designed by the addition of hetero-aromatic moieties including pyridine, quinoline
and isoquinoline moieties attached to the 14-position of naltrexone through an ester
linkage.

The addition of the hetero-aromatic to the 14-position of naltrexone may
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provide essential hydrogen bonding to interact with Trp318 in the aromatic binding
pocket in the mu-opioid receptor and confer higher selectivity to the mu-opioid receptor.
The second series of selective non-peptidyl mu-opioid receptor antagonists were
6-N-heterocylic substituted naltrexamines.

These antagonists contain a heterocyclic

moiety including pyridine, quinoline, and isoquinoline linked at the 6-position of
naltrexamine through an amide bond. The aromatic character of the heterocylic moiety
may help provide hydrogen bonding interaction with the aromatic binding pocket in the
mu-opioid receptor.

Also the α and β stereochemical arrangements were tested to

determine if they play a role in selectivity to the mu-opioid receptor.
Finally, for both series of compounds, phenyl and napthalenyl compounds were
used as controls to test the hypothesis that the addition of heterocyclic moieties to
naltrexone and naltrexamine’s backbone will provide hydrogen bonding with Trp318 in
EL3 of the binding pocket of the mu-opioid receptor. Chemical synthesis of the 14-Oheterocylic substituted naltrexone derivatives was conducted in a “one-pot” reaction
condition by the direct coupling of the heterocyclic moiety to the 3- and 14-positions of
naltrecxone. This is followed by the selective removal of the heterocylic moiety at the 3position of naltrexone. Finally these compounds were converted into dihydrochloride
salts except for compound 21. Although most compounds were synthesized easily in the
above manner, some difficulty was encountered in the synthesis of compounds 17, 20 and
24.
Following chemical synthesis of the selective non-peptidyl mu-opioid receptor
antagonist, biological evaluation was conducted to determine the affinity and selectivity
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of these compounds for the mu-, delta-, and kappa-opioid receptors. Besides the test of
their affinities, these compounds were also characterized for their potential agonist
activity using a functional [35S]GTPγS assay.
For the first series of compounds, the 14-O-heterocylcic substituted naltrexone
derivatives, all of these compounds, except for the controls, displayed higher selectivity
for the mu-opioid receptor compared to the delta- and kappa-opioid receptors.
Additionally, all of the compounds displayed an antagonist activity profile. Compounds
17 and 22 were identified as lead compounds with comparable affinity with naltrexone
for the mu-opioid receptor but much higher selectivity for the mu-opioid receptor over
the kappa- and delta-opioid receptors. Although compound 17 has similar affinity to the
mu-opioid receptor compared to naltrexone but it has much higher selectivity to the muopioid receptor compared to naltrexone. Compound 22 also carries higher selectivity to
the mu-opioid receptor compared to naltrexone though its binding affinity is about ten
times lower than that of naltrexone.
The second series of compounds, 6-N-heterocylcic substituted naltrexamine
derivatives, display similar affinity and selectivity compared to the 14-O-heterocylcic
substituted naltrexone derivatives. Compounds 26 and 35 have been identified as a lead
compound with a 10-fold decrease in affinity compared with naltrexone for the muopioid receptor but higher selectivity, about 40- and 49-fold respectively, for the muopioid receptor over the kappa-opioid receptors. DAMGO, a full mu-opioid receptor
agonist, has been used to compare and determine agonistic characteristics of all of the
compounds. All of the compounds are partial mu-opioid receptor agonists while the lead
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compounds 26 and 35 have about 29.11% and 15.83% agonist activity compared to
DAMGO, respectively.
For both series of compounds it is important to note that the controls which lacks
an heterocyclic moiety to provide hydrogen bonding with EL3 for the mu-opioid receptor
also showed much lower selectivity to the mu-opioid receptor. Therefore, it is clear that
the nitrogen in the aromatic moieties is necessary for higher binding affinity to the muopioid receptor compared to the delta- and kappa-opioid receptors.
In order to get a better understanding of how these compounds are binding to the
mu-opioid receptor, a homology modeling study of the mu-opioid receptor was
conducted. The homology model of the mu-opioid receptor was built using the crystal
structure of the dark state bovine rhodopsin as the template. Docking simulations of each
ligand in the homology model of the mu-opioid receptor were then conducted and Gold
scores were determined for each ligand. The Gold docking scores did not correlate very
well with the affinities determined in the biological evaluation studies.

The lead

compound 22 displayed the highest Gold score of all of these derivatives.

Lead

compound 17 also displays a high Gold score. Naltrexone showed one of the lowest
Gold docking scores compared to the designed compounds and may be due to the weaker
interaction of naltrexone in the binding pocket.
In summary, from the first series of 14-O-heterocylcic substituted naltrexone
derivatives, compounds 17 and 22 were determined to be the lead compounds using both
competition binding assays for all three opioid receptors and functional assays to
determine their agonist activity profile.

Although compounds 14-O-heterocylcic
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substituted naltrexone derivatives 17 and 22 display similar or lower affinity to the muopioid receptor compared to naltrexone, they both displayed much higher selectivity.
From the second series of 6-N-heterocylic substituted naltrexamine derivatives, two lead
compounds were identified, 26 and 38. Both of these compounds have high selectivity
and affinity to the mu-opioid receptor. Both of these compounds also display partial
agonist activity a the mu-opioid receptor compared to DAMGO in the [35S]GTPγS
functional binding assay. Further optimization of these lead compounds may lead us to a
potent and highly selective mu-opioid receptor antagonist with diminished agonist
activity.

VI. Experimental
1.

Chemical Synthesis of 14-O-Heterocyclic Substituted Naltrexone Derivatives
Two synthetic routes are applied to synthesize the 14-O-heterocyclic substituted

naltrexone derivatives. The first synthetic route is adapted when the starting material is
an acyl chloride while the second is for the starting material as a carboxylic acid.92,93 All
compounds are characterized by 1H-NMR,

13

C-NMR, MS and IR. Melting points are

determined by Fischer Scientific melting point apparatus. The 1H-NMR (300 MHz) and
13

C-NMR (75 MHz) spectra are obtained on a Varian Gemini spectrometer and

tetramethylsilane is used as the internal standard. Mass spectrometer spectra are obtained
using direct-infusion ESI-MS-MS.

Samples are diluted 1:100 with methanol and

introduced into a Quattro II triple quadruple mass spectrometer with an electrospray ion
source (Micromass, Altrincham, England) at a flow rate of 10 mL/min using a Harvard
Apparatus Syringe Pump model 11 (Holliston, MA).

The samples are analyzed in

negative ion mode with a capillary voltage of 2.3 kV, cone 30V, and extractor 5V. IR
spectra are obtained using a Nicolet 5ZDX FT-IR spectrometer with potassium bromide
as the background. Column chromatography is performed by using silica gel (grade 60
mesh; Bodman Industries, Ashton, PA). Routine thin-layer chromatography (TLC) is
performed on silica gel GHIF plates (250 μ, 2.5 x 10 cm, Analtech Inc. Newark, DE). All
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the compounds are converted to salts with 2.2 equivalents of 1.25 molar hydrogen
chloride acid in methanol (Fluka).

1.1

Synthetic Route A: Acyl Chloride
One equivalent of naltrexone (NTX) is dissolved in 5 mL of DMF. Then 2.2

equivalents of the acyl chloride and 4.4 equivalents of TEA are added. The reaction
mixture is heated at reflux for 4 h under N2 atmosphere. The reaction mixture is then
cooled

down

and

TLC

is

conducted

to

monitor

the

reaction

(40:1:0.01

CH2Cl2:MeOH:NH3H2O).
The reaction mixture is transferred to a large round bottom flask; 20 mL of 4%
H2SO4 and 20 mL of MeOH are added to the mixture and stirred for 4 h at room
temperature. TLC is taken again to monitor the reaction. The reaction mixture is
neutralized by adding a dilute solution of ammonium hydroxide in a dropwise manner
until it reached a pH of 7. The solvents are evaporated under reduced pressure and the
residue is purified by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O). The
final compound is converted into a hydrochloride salt and stored in the freezer.

1.2

Synthetic Route B: Carboxylic Acids
In order to convert the carboxylic acid to an acyl chloride, the carboxylic acid is

dried using a vacuum pump and toluene is dried overnight under 4Å molecular sieves.
An excess amount of thionyl chloride (SOCl2) is added to the carboxylic acid and then
heated at reflux continuously under N2 atmosphere for 3 h. The reaction mixture is then
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immediately distilled under N2 atmosphere by the addition and distillation of dried
toluene three times to remove all of the excess SOCl2.
One equivalent of pre-dried NTX is added to the reaction mixture containing the
acyl chloride and dissolved in 5 mL of DMF. Then 4.4 equivalents of TEA is added to
the reaction mixture. The reaction mixture is heated at reflux at for 4 h under N2
atmosphere. The reaction mixture is then cooled down and TLC was conducted to
monitor the reaction (40:1:0.1 CH2Cl2:MeOH:NH3H2O).
Next, the reaction mixture is transferred to a large round bottom flask. Then 20
mL of 4% H2SO4 and 20 mL of MeOH are added to the reaction mixture and stirred for 4
h at room temperature. TLC is taken again to monitor the reaction. The reaction mixture
is neutralized by adding a dilute solution of ammonium hydroxide in a dropwise manner
till it reached a pH of 7. The solvents are evaporated under reduced pressure and the
residue is purified by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O). The
final compound is converted to a hydrochloride salt and stored in the freezer.

2.

Final Compounds

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl2’carboxy)morphinan-6-one (17)
Following procedure B, picolinic acid (492 mg, 4.0 mmol), SOCl2 (5 mL), DMF (5 mL),
naltrexone (341 mg, 1.0 mmol) and TEA (1.12 mL, 809 mg, 8.0 mmol), are applied. The
reaction mixture is heated at reflux overnight under a nitrogen atmosphere. A black
residue is obtained and purified by column chromatography (200:1:0.04 and 100:1:0.04
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CH2Cl2:MeOH:NH3H2O) system and 225 mg (50.0% yield) of a red oil is isolated and
converted to hydrochloride salt. 1H-NMR (300 MHz, CDCl3) (free base) δ 0.58 (m, 4H),
1.12 (m, 1H), 1.91 (m, 2H), 2.47 (m, 2H), 2.72 (m, 2H), 3.09 (m, 2H), 3.15 (m, 2H), 3.21
(m, 2H), 3.36 (m, 1H), 3.50 (b, 1H, D2O exchangeable), 4.68 (m, 1H), 6.61 (d, J=8.1 Hz,
1H), 6.74 (d, J=8.1 Hz, 1H), 7.27 (m, 1H), 7.63 (m, 1H), 7.80 (m, 1H), 8.60 (m, 1H); 1HNMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.86 (m, 4H), 1.25 (m, 1H), 1.35 (m,
1H), 1.72 (b, 1H, D2O exchangeable), 2.10 (b, 1H, D2O exchangeable), 2.28 (m, 2H),
2.32 (m, 2H), 2.84 (m, 2H), 3.05 (m, 2H), 3.21 (m, 2H), 3.33 (m, 1H), 4.11 (m, 1H), 4.89
(b, 1H, D2O exchangeable), 6.67 (d, J=6.6 Hz, 1H), 6.75 (d, J=6.6 Hz, 1H), 8.18 (m, 1H),
8.23 (m, 1H), 8.70 (m, 1H), 8.96 (m, 1H); 13C-NMR (75 MHz, CD3OD) (dihydrochloride
salt) δ 1.56, 4.34, 4.97, 22.49, 26.90, 27.89, 29.30, 30.23, 34.17, 37.51, 52.99, 56.92,
61.69, 69.52, 88.54, 117.95, 119.98, 125.40, 127.39, 129.90, 138.89, 139.87, 142.36,
146.38, 161.31, 207.59; IR (cm-1) 794.26, 1259.60, 1660.32, 3411.85; MS m/z (relative
intensity, ion): 447.0 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl4’carboxy)morphinan-6-one (18)
Following procedure A, isonicotinyl chloride (534 mg, 3.0 mmol, 3 equivalents),
naltrexone (341 mg, 1.0 mmol), DMF (5 mL), and TEA (0.84 mL, 607 mg, 6.0 mmol, 6
equivalents), are applied. Product is isolated by column chromatography (60:1:0.04
CH2Cl2:MeOH:NH3H2O) and 310 mg (69.0% yield) of a bright yellow powder is
obtained and converted to hydrochloride salt. mp 190-195 °C;

1

H-NMR (300 MHz,
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CDCl3) (free base) δ 0.58 (m, 4H), 0.89 (m, 1H), 1.66 (m, 2H), 1.93 (m, 2H), 2.18 (m,
2H), 2.46 (m, 2H), 2.74 (m, 2H), 3.03 (m, 2H), 3.95 (m, 1H), 4.73 (b, 1H, D2O
exchangeable), 5.30 (m, 1H), 6.75 (d, J=8.1 Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 8.02 (m,
2H), 8.84 (m, 2H); 1H-NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.82 (m, 4H),
1.18 (m, 1H), 1.76 (b, 1H, D2O exchangeable), 2.13 (m, 2H), 2.32 (b, 1H, D2O
exchangeable), 2.83 (m, 2H), 2.97 (m, 2H), 3.10 (m, 2H), 3.19 (m, 2H), 3.46 (m, 2H),
4.08 (m, 1H), 4.20 (m, 1H), 5.10 (b, 1H, D2O exchangeable), 7.05 (d, J=8.1 Hz, 1H), 7.27
(d, J=8.1 Hz, 1H), 8.74 (m, 2H), 9.18 (m, 2H);

13

C-NMR (75 MHz, CD3OD)

(dihydrochloride salt) δ 2.46, 5.23, 5.80, 23.81, 27.71, 30.97, 34.68, 57.76, 62.11, 69.69,
70.16, 90.43, 120.88, 121.02, 123.80, 127.02, 127.53, 129.13, 129.71, 132.56, 143.50,
145.32, 147.69, 149.17, 160.13, 207.27; IR (cm-1) 748.57, 1241.13, 1270.34, 1724.55,
1755.48, 3385.42; MS m/z (relative intensity, ion): 446.8 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(pyridinyl3’carboxy)morphinan-6-one (19)
Following procedure A, nicotinyl chloride (356 mg, 2.0 mmol), naltrexone (300 mg, 0.9
mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), are applied. Product is
isolated by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O) and 105 mg
(24.1% yield) of a white fluffy powder is obtained and converted to hydrochloride salt.
mp 202°C (decomposed); 1H-NMR (300 MHz, CD3Cl) (free base) δ 0.52 (m, 4H), 1.19
(m, 1H), 1.71 (m, 2H), 1.86 (m, 2H), 2.26 (m, 2H), 2.34 (m, 2H), 2.65 (m, 2H), 2.78 (m,
2H), 3.00 (m, 1H), 3.67 (b, 1H, D2O exchangeable), 4.67 (m, 1H), 6.65 (d, J=7.8 Hz,
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1H), 6.75 (d, J=7.8 Hz, 1H), 7.52 (m, 1H), 8.45 (m,1H), 8.86 (m, 1H), 9.56 (s, 1H); 1HNMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.86 (m, 4H), 1.20 (m, 1H), 1.31 (m,
2H), 1.74 (b, 1H, D2O exchangeable), 2.03 (b, 1H, D2O exchangeable), 2.13 (m, 2H),
2.86 (m, 2H), 3.15 (m, 2H),3.33 (m, 2H), 3.41 (m, 2H), 3.59 (m, 1H), 4.08 (m, 1H), 5.39
(d, J=5.4 Hz, 1H), 5.63 (d, J=5.4 Hz, 1H), 6.75 (b, 1H, D2O exchangeable), 8.28 (m, 1H),
9.14 (m, 1H), 9.28 (m, 1H), 9.63 (s, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ 3.30,
3.46, 9.00, 22.87, 26.56, 30.30, 35.29, 43.47, 50.85, 55.33, 58.86, 89.35, 93.97, 118.21,
119.76, 123.37, 123.75, 127.42, 137.42, 137.56, 139.31, 143.14, 149.96, 152.17, 163.37,
207.43; IR (cm-1) 737.60, 1108.04, 1282.53, 1716.37, 2946.50; MS m/z (relative
intensity, ion): 447.0 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(benzoylcarboxy)morphinan-6one (20)
Following procedure A, benzoyl chloride (281 mg, 2.0 mmol), naltrexone (300 mg, 0.9
mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), are applied. The next step
involving dilute H2SO4 and MeOH is unable to remove the benzyl group at the 3position. The reaction mixture is concentrated and stored in freezer overnight. In order
to remove the benzyl group at the 3-position, the 200 mg of the di-substituted product is
dissolved in 20 mL of THF and 5 mL of a saturated K2CO3 aqueous solution that is
diluted by half. The mixture is stirred overnight at room temperature. Next, the mixture
is separated into a THF layer and water layer. The water layer is extracted with 40 mL of
CH2Cl2 (3 times) and the combined organic layers are dried and concentrated. The

104
product is isolated and purified by column chromatography (200:1:0.04 and 100:1:0.04
CH2Cl2:MeOH:NH3H2O).

About 40 mg (10.2% yield) of a light yellow powder is

obtained and converted to hydrochloride salt. mp 161-165°C; 1H-NMR (300 MHz,
CDCl3) (free base) δ 0.60 (m, 4H), 1.25 (m, 1H), 1.88 (m, 2H), 2.18 (m, 2H), 2.42 (m,
2H), 2.62 (m, 2H), 2.68 (m, 2H), 2.98 (m, 2H), 3.05 (m, 1H), 3.27 (m, 1H), 4.72 (b, 1H,
D2O exchangeable), 6.73 (d, J=8.1 Hz, 1H), 6.96 (d, J=8.1 Hz, 1H), 7.49 (m, 2H), 7.62
(m, 1H), 8.21 (m, 2H); 1H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.90
(m, 4H), 1.30 (m, 1H), 1.79 (b, 1H, D2O exchangeable), 1.95 (m, 2H), 2.10 (m, 2H), 2.47
(m, 2H), 2.74 (m, 2H), 2.84 (m, 2H), 2.90 (m, 2H), 3.01 (m, 1H), 3.33 (m, 1H), 4.88 (b,
1H, D2O exchangeable), 7.00 (d, J=9.1 Hz, 1H), 7.14 (d, J=9.1 Hz, 1H), 7.61 (m, 2H),
7.73 (m, 1H), 8.21 (m, 2H);

13

C-NMR (75 MHz, CD3OD) (monohydrochloride salt) δ

1.56, 4.34, 4.91, 22.87, 26.89, 30.03, 33.76, 56.98, 58.09, 61.64, 62.11, 69.12, 69.35,
89.12, 93.10, 96.46, 119.74, 122.50, 123.44, 129.31, 129.39, 132.18, 132.66, 133.52,
147.54, 163.72, 205.92; IR (cm-1) 709.97, 1055.29, 1238.92, 1729.47, 3398.92; MS m/z
(relative intensity, ion): 447.0 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(isoquinolinyl-3’carboxy)morphinan-6-one (21)
Following procedure B, 3-isoquinoline carboxylic acid (381 mg, 2.2 mmol), SOCl2 (5
mL), naltrexone (341 mg, 1.0 mmol), DMF (5 mL), and TEA (0.61 mL, 445 mg, 4.4
mmol) is applied.

Product is isolated by column chromatography (200:1:0.04

CH2Cl2:MeOH:NH3H2O) and 117 mg (23.6% yield) of a dark yellow powder is isolated
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and converted to hydrochloride salt. mp 201-204°C; H-NMR (300 MHz, CDCl3) (free
1

base) δ 0.38 (m, 4H), 1.18 (m, 1H), 1.27 (m, 2H), 1.70 (m, 2H), 2.98 (m, 2H), 3.02 (m,
2H), 3.06 (m, 2H), 3.19 (m, 2H), 3.28 (m, 1H), 3.66 (b, 1H, D2O exchangeable), 4.74 (m,
1H), 6.78 (d, J=8.1 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.89 (m, 3H), 8.06 (m, 1H), 8.46 (s,
1H), 8.73 (s, 1H); 1H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.84 (m,
4H), 1.15 (m, 1H), 1.30 (m, 2H), 1.73 (m, 2H), 2.04 (m, 2H), 2.33 (b, 1H, D2O
exchangeable), 2.78 (m, 2H), 3.33 (m, 2H), 3.46 (m, 2H), 3.59 (m, 1H), 3.64 (b, 1H, D2O
exchangeable), 4.03 (m, 1H), 7.01 (d, J=8.1 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 8.01 (m,
3H), 8.25 (m, 1H), 8.50 (s, 1H), 8.87 (s, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ
3.45, 3.62, 8.97, 22.61, 30.38, 30.79, 43.05, 50.25, 53.68, 58.79, 61.48, 69.63, 90.27,
119.05, 122.62, 125.01, 126.34, 128.16, 128.34, 129.20, 129.85, 130.19, 130.75, 131.66,
132.23, 136.64, 138.94, 147.36, 161.70, 207.23; IR (cm-1) 781.33, 1182.05, 1724.96,
2920.65, 3392.46; MS m/z (relative intensity, ion): 497.4 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(quinolinyl-2’carboxy)morphinan-6-one (22)
Following the above procedure A, quinaldyl chloride (383 mg, 2.0 mmol), naltrexone
(300 mg, 0.9 mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.0 mmol), is applied.
Product is isolated by column chromatography (50:1:0.04 CH2Cl2:MeOH:NH3H2O) and
76 mg (17.4% yield) of a white powder is obtained and converted to hydrochloride salt.
mp 85-88°C; 1H-NMR (300 MHz, CDCl3) (free base) δ 0.18 (m, 4H), 0.59 (m, 1H), 1.29
(m, 2H), 1.66 (m, 2H), 1.94 (m, 2H), 2.36 (m, 2H), 2.76 (m, 2H), 3.10 (m, 2H), 3.24 (m,
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1H), 3.68 (b, 1H, D2O exchangeable), 4.73 (m, 1H), 6.61 (d, J=4.8 Hz, 1H), 6.62 (d,
J=4.8 Hz, 1H), 6.76 (m, 1H), 6.79 (m, 1H), 7.29 (m, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.61 (d,
J=8.1 Hz, 1H), 7.86 (m, 1H); 1H-NMR (300 MHz, CD3OD) (dihydrochloride salt) δ 0.82
(m, 4H), 1.28 (m, 1H), 1.71 (m, 2H), 1.94 (b, 1H, D2O exchangeable), 2.31 (b, 1H, D2O
exchangeable), 2.92 (m, 2H), 3.07 (m, 2H), 3.24 (m, 2H), 3.43 (m, 2H), 3.56 (m, 2H),
4.07 (m, 1H), 4.20 (m, 1H), 5.08 (b, 1H, D2O exchangeable), 7.00 (d, J=8.1 Hz, 1H), 7.26
(d, J=8.1 Hz, 1H), 7.92 (m, 1H), 8.08 (m, 1H), 8.24 (m, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.50
(d, J=8.4 Hz, 1H), 8.99 (m, 1H); 13C-NMR (75 MHz, CD3OD) (free base) δ 3.39, 3.62,
8.96, 22.20, 30.18, 30.94, 35.79, 43.20, 50.60, 58.76, 61.56, 69.90, 90.06, 115.70, 117.66,
119.50, 121.09, 122.34, 123.52, 127.38, 128.51, 130.28, 131.41, 133.72, 138.64, 140.65,
143.11, 143.76, 163.00, 209.92; IR (cm-1) 729.62, 1240.22, 1453.50, 1660.32, 1731.42,
3179.17; MS m/z (relative intensity, ion): 497.1 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(quinolinyl-3’carboxy)morphinan-6-one (23)
Following procedure B, 3-quinoline carboxylic acid (366 mg, 1.9 mmol), SOCl2 (5 mL),
naltrexone (307 mg, 0.9 mmol), DMF (5 mL), and TEA (0.51 mL, 364.3 mg, 3.5 mmol),
is

applied.

Product

is

isolated

by

column

chromatography

(60:1:0.04

CH2Cl2:MeOH:NH3H2O) and 104 mg (21.7% yield) of a light yellow powder is obtained
and converted to hydrochloride salt. mp 187°C (decomposed); 1H-NMR (300 MHz,
CDCl3) (free base) δ 0.38 (m, 4H), 0.93 (m, 1H), 1.80 (m, 2H), 2.05 (m, 2H), 2.28 (m,
2H), 2.40 (m, 2H), 2.70 (m, 2H), 3.08 (m, 2H), 3.15 (m, 1H), 3.28 (b, 1H, D2O
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exchangeable), 4.74 (m, 1H), 6.83 (d, J=8.1 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.67 (m,
1H), 7.83 (m, 1H), 7.92 (m, 1H), 8.15 m, 1H), 9.07 (s, 1H), 9.61 (s, 1H); 1H-NMR (300
MHz, CDOH) (dihydrochloride salt) δ 0.86 (m, 4H), 1.20 (m, 1H), 1.86 (b, 1H, D2O
exchangeable), 2.00 (b, 1H, D2O exchangeable), 2.12 (m, 2H), 2.25 (m, 2H), 2.75 (m,
2H), 3.02 (m, 2H), 3.15 (m, 2H), 3.33 (m, 2H), 3.49 (m, 1H), 4.25 (m, 1H), 7.08 (d, J=8.1
Hz, 1H), 4.95 (b, 1H, D2O exchangeable), 7.27 (d, J=8.1 Hz, 1H), 7.93 (m, 1H), 8.32 (m,
3H), 9.58 (s, 1H), 9.64 (s, 1H);

13

C-NMR (75 MHz, CD3OD) (dihydrochloride salt) δ

1.63, 4.42, 4.97, 13.57, 22.96, 26.93, 30.16, 33.87, 56.97, 61.44, 64.98, 69.37, 89.52,
120.07, 122.14, 123.29, 123.67, 127.06, 128.19, 128.44, 129.02, 129.70, 132.07, 134.83,
143.32, 144.14, 146.82, 147.10, 160.69, 206.38; IR (cm-1) 761.94, 1188.51, 1724.96,
3386.00; MS m/z (relative intensity, ion): 497.1 (100%, (M+H)+).

17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-O-(napthalenyl-2’carboxy)morphinan-6-one (24)
Following procedure A, 2-napthoyl chloride (419.3 mg, 2.2 mmol), naltrexone (341 mg,
1.0 mmol), DMF (5 mL), and TEA (0.56 mL, 405 mg, 4.4 mmol), is applied. The next
step involving dilute H2SO4 and MeOH is unable to remove the naptholene group at the
3-position. The reaction mixture is concentrated and stored in freezer overnight.

About

387 mg of di-substituted product is obtained. So in order to remove the naptholene
moiety at the 3-position, 200 mg of the di-substituted product is dissolved in 20 mL of
THF and 5 mL of a saturated K2CO3 aqueous solution that is diluted by half. The
mixture is stirred overnight at room temperature. Next the mixture is separated into a
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THF layer and water layer. The water layer is extracted with 40 mL of CH2Cl2 (3 times)
and the combined organic layers are dried and concentrated. The product is isolated by
column chromatography (200:1:0.04 and 100:1:0.04 CH2Cl2:MeOH:NH3H2O). About 35
mg (7.1% yield) of a light brown powder was isolated and converted to hydrochloride
salt. mp 137-140°C; 1H-NMR (300 MHz, CDCl3) (free base) δ 0.40 (m, 4H), 1.25 (m,
1H), 1.93 (m, 2H), 2.75 (m, 2H), 3.04 (m, 2H), 3.38 (m, 2H), 3.45 (m, 2H), 3.70 (m, 2H),
3.88 (m, 1H), 4.04 (m, 1H), 5.09 (b, 1H, D2O exchangeable), 6.76 (d, J=8.1 Hz, 1H), 7.01
(d, J=8.1 Hz, 1H), 7.60 (m, 2H), 7.90 (m, 2H), 7.99 (m, 1H), 8.20 (m, 1H), 8.81 (s, 1H);
1

H-NMR (300 MHz, CD3OD) (monohydrochloride salt) δ 0.91 (m, 4H), 1.20 (m, 1H),

1.34 (m, 2H), 1.86 (b, 1H, D2O exchangeable), 2.16 (m, 2H), 2.53 (m, 2H), 3.53 (m,
2H), 3.89 (m, 2H), 4.07 (m, 2H), 4.19 (m, 1H), 4.39 (m, 1H), 4.77 (b, 1H, D2O
exchangeable), 7.02 (d, J=8.1 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 7.70 (m, 2H), 8.10 (m,
4H), 8.97 (s, 1H);

13

C-NMR (75 MHz, CD3OD) (monohydrochloride salt) δ 1.50, 4.39,

4.92, 22.86, 26.90, 33.79, 56.96, 61.65, 69.37, 76.69, 89.18, 93.17, 96.52, 119.17, 119.80,
122.32, 123.53, 124.37, 126.62, 127.04, 127.36, 127.72, 128.15, 128.70, 131.25, 121.53,
132.02, 132.78, 135.49, 164.81, 206.04; IR (cm-1) 775.87, 1055.98, 1188.70, 1731.54,
3386.00; MS m/z (relative intensity, ion): 496.0 (100%, (M+H)+).
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3.

Pharmacological Studies

3.1

Cell Culture
Cells expression the mu-, delta-, and kappa-opioid receptors are grown and

harvested in order to test the affinities of the naltrexone derivatives. Chinese hamster
ovary (CHO) cells that over expressed the mu-opioid receptor (Dr. Dana Selley’s
laboratories at VCU) and kappa-opioid receptor (Dr. Ping Law at University of
Minnesota) are grown. For the delta-opioid receptor, four different cell lines that over
expressed the delta-opioid receptor are utilized for testing the naltrexone derivatives. The
first set of cell lines tested consisted of two CHO cell lines (Dr. Ping Law from the
University of Minnesota and Dr. Liu-Chen at Temple University) and human embryonic
kidney 293 (HEK) cells (Dr. Ping Law from the University of Minnesota). The final cell
line used is the NG108-15 neurohybrid (Mouse Neuroblastoma x Rat Glioma hybrid) cell
line because it naturally expresses the delta-opioid receptor (Dr. Dana Selley’s
laboratories at VCU).

A.

Cell Culture Protocol
Similar protocols are used employed to grow and harvest all of the cell lines used

for the pharmacology studies. However, there are some differences in media used for
each cell line.

Freezebacks of each cell line are obtained from their respective

laboratories.
First, the cells are put into a 15 mL falcon tube with complete media and spun
down at 5000 rpm for 5 minutes. Complete media consists of FBS (Fetal Bovine Serum,
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USDA approved, Invitrogen), G418 (Genetecin, Invitrogen), and Penicillin/Streptomycin
(Invitrogen). For the NG108-15 and HEK cell lines, 1.5M Hepes (Mediatech) is added
for a final concentration of 15 mM.

Plain media is just media with no additional

additives.
After the cells are spun down, the supernatant is poured off and the pellet is resuspended in 10 mL of complete media. Next, the cells are plated in a tissue dish (100 x
20 mm, Fischer) with complete media and placed in the incubator set at 37 °C with 5%
CO2 and 95% humidity. The cells are left until they were about 80% confluent and then
passed from 1 to 4 tissue dishes by pouring off the old media and adding 4 mL of Trypsin
with 0.05% EDTA (Invitrogen). The cells are put back into the incubator for 3 to 5
minutes until all the cells were detached from the tissue dish. Then 4 mL of complete
media is added to the cells. Next, 2 mL of the cells in media are added to each tissue
dish. Then the cells are placed back into the incubator until they are confluent, this takes
about 1 to 2 days depending on the cell line. Two plates are then passed the same way
from 2 to 8 tissue dishes. The other 2 tissue dishes are frozen down to create more
freezebacks.
After the second passage there are 8 tissue dishes. When the cells are confluent,
they are transferred into 8 flasks (175 cm2, Corning) by pouring off the old media and
adding 4 mL of trypsin. Then the cells from each tissue dish are added into separate
flasks. About 25 mL of complete media is added to each of the flasks and placed back
into the incubator. When the cells in the flasks are confluent, they are harvested by
adding 6 mL of trypsin and put back into incubator for 10 to 15 minutes until all of the
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cells detached from the flask. Then 6 mLs of complete media is added and the flasks
were rinsed about 10 times to break up the cells. About 9 mL of cells are added into
falcon tubes and 1 mL of cells was left in the bottom of each flask. Finally, 25 mL of
complete media is added to the flasks and put back into incubator.
The cells in the falcon tubes are spun down at 5000 rpm for 5 minutes. The
supernatant is poured off and the cells were re-suspended in 30 mL of 1X PBS (100mL of
10X PBS liquid concentrated in 900 mL deionized water, VWR) and spun down at 5000
rpm for 5 minutes. About 10 mL of TME with no NaCl is added and transferred into a
polypropylene centrifuge tube. The cells are spun down again at 50,000 x g for 10
minutes at 4 °C. The supernatant is poured off and then 5 mL of TME with no NaCl is
added and homogenized for 30 seconds. Next, a Bradford protein determination is run on
the cells and the cells are divided into 3 mg portion in 2 mL cryovials (Corning) and
frozen at -80 °C. The cells are passed until they reach their 20th passage each time
following the above procedure.

B.

Freezeback Protocol
The freezebacks are created by pouring off the old media and adding 3 mLs of

trypsin to each plate. When all of the cells detach from the tissue dish, they are put in a
falcon tube and spun down at 5000 rpms for 5 minutes. The supernatant is poured off
and 2 mL of a freezeback solution was added. The freezeback solution contains the
appropriate media for the cells as well as 10% FBS and 10% sterile DMSO (Research
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Organic Inc.). The cells are aliquoted into two 1 mL portions in cryovials and put into a 20 °C freezer for 30 minutes and then moved to the -80 °C freezer for long-term storage.

C.

Cell Media Recipe
Each of the cell lines used in the pharmacology studies has a different media

recipe and two types of media were used for the cells.

The CHO cell lines use

DMEM/F12 (Invitrogen) and the HEK 293 and NG108-15 cell lines use DMEM
(Invitrogen) media. The cell media also contains additives including FBS, G418, and
Penicillin/Streptomycin.
A solution of 50 mg/mL of G418 is made by dissolving 5 g of G418 in 100 mL of
HBSS (Hank’s Balanced Salt Solution, Invitrogen) without Ca2+ and Mg2+ media. Then
the pH of the solution is adjusted to 7.4 by the addition of 1N NaOH. The solution is
stored in 10 mL portions in the -20 °C freezer till needed.
For the NG108-15 and DORHEK cells, a 1.5 M HEPEs solution is added. This is
made by making a 1.5 M (35.7 g) HEPEs solution in 100 mL of deionized water. Then
the solution is sterile filtered (Stericup Disposable Vacuum Filtration System, 22 μm,
Millipore, Bedford, MA) under the hood. The solution is stored in 4 °C refrigerator until
needed.
The FBS is prepared by thawing it overnight in 4 °C refrigerator. When the FBS
is completely thawed, it is heat inactivated by placing it in a water bath set at 56 °C for
30 minutes. Then the FBS is aliquoted in 100 mL portions into autoclaved bottles. These
bottles are then stored in the freezer set at -20 °C until needed.
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The media for the DORHEK cells consists of DMEM media with 8% FBS (40
mL), 1% Penicillin/Streptomycin (5 mL), 1.5 mM Hepes (5 mL), and 0.2 mg/mL G418
(2 mL). The media prepared for the DORCHO cells consists of DMEM/F12 with 10%
FBS (50 mL), 1% Penicillin/Streptomycin (5 mL) and 0.2 mg/mL G418 (2 mL).
The media prepared for the KORCHO and MORCHO cells consists of
DMEM/F12 with 5% FBS (25 mL), 1% Penicillin/Streptomycin (5 mL) and 0.2 mg/mL
G418 (2 mL). The DORCHO cells used the same media recipe except it contained 10%
FBS (50mL) instead of 5% FBS.
For the NG108-15 cells the media is prepared similar to the DORHEK cells with
DMEM media containing 10% FBS (50 mL), 1% Penicillin/Streptomycin (5 mL), 1.5
mM HEPEs (5 mL), and 0.2 mg/mL G418 (2 mL). For NG108-15 cells, 2 bottles of a
50X HAT supplement (final concentration 200 μM Hypoxanthine, 0.8 μM Aminopterin,
and 32 μM thymidine, Hybrimax) is added by dissolving the HAT powder in 10 mL of
deionized water and adding it directly to the media.

3.2

Preparation of Naltrexone and Naltrexamine Derivatives for Radiolabeled

Binding Assays
The 14-O-heterocyclic substituted naltrexone derivatives and the 6-N-heterocyclic
substituted naltrexamine derivates are prepared for the binding assays by drying them on
a vacuum pump for at least 2 h. Then 2 mM stock concentrations of the compounds are
prepared by first dissolving the compound in a drop of DMSO and using a vortex to mix
the compound until it was completely dissolved. Then 1 mL of deionized water is added
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and mixed again using a vortex. Finally, the compound is aliquoted into 50 μL portions
and stored at -20 °C freezer till needed.
The above procedure is followed for all of the compounds except compound 17.
Compound 17 is insoluble in deionized water so it was dissolved in 70% DMSO and 30%
deionized water to make the 2 mM stock solution.

3.3

Radiolabeled Binding Assays

A.

Saturation or Scatchard Radiolabeled Binding Assay
The saturation ligand-binding assay is the main technique used in the

determination of the availability of the receptors. In this assay, receptors are incubated
with increasing concentrations of radiolabeled ligand. From this assay the Bmax, the
density or the maximum number of binding sites, and Kd, dissociation constant of the
radioligand, is determined.101 The saturation assay is conducted for the KORCHO,
DORCHO and DORHEK cell lines from the University of Minnesota. Other cell lines
used includes MORCHO and NG108-15 cell lines from Dr. Selley’s laboratories at
Virginia Commonwealth University and DORCHO cells from Temple University but the
saturation assay was not conducted for these cell lines.
The buffer that was used in this experiment is TME without NaCl (24.27 g Tris,
50 mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 4 L DI water and pH adjusted
to 7.7 at room temperature).

For this particular assay there will be 8 different

concentrations of [3H] radioligand ranging from 0.01 nM to 2.0 nM.

All the

concentrations are done in triplicate with each concentration having non-specific tubes
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also in triplicate. The non-specific binding is measured with the addition of same ligand
as the radioligand but not labeled with tritium. The total volume in each tube is 500 μL.
For the total binding it will include the cells, radioligand, and TME without NaCl. For
non-specific binding it will include all of the components in total binding as well as the
addition of cold ligand.
Below is a general step-by-step protocol for the saturation binding assay.
However, some changes are made in certain cases discussed in the discussion and results
section.
Preparation of Protein
1.

Remove cells from -80 °C freezer and thaw. Add about 5mL of TME
buffer with no NaCl into the centrifuge tube for every cell aliquot used.
NOTE: Keep all buffers, compounds and cells on ice at all times!

2.

Vortex cells to make sure the cells are completely dissolved in the buffer.

3.

Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10
minutes at 10 °C.

4.

Pour out the supernatant and keep the pellet. Re-suspend the pellet in
about 3 to 4 mLs of the TME buffer with no NaCl for every tube of cells
used.

5.

Homogenize the cells to make sure they are completely dissolved in the
buffer. Keep the cells on ice.

6.

116
Conduct the Bradford Protein Determination Assay using BSA (Bovine
Serum

Albumin)

as

standards

using

a

Beckman

DU

640

Spectrophotometer.
Saturation/Scatchard Assay
1.

Propylene culture tubes (12x75 mm) were numbered and placed in racks
on ice.

2.

First add the appropriate amount of TME with No NaCl to all the culture
tubes. Note: Follow spreadsheet made with concentrations and amounts
of drugs to add to the tubes. Normally final volume will be 500 μL per
tube.

3.

For this assay, there are 8 different concentrations of the radioligand used
ranging from 0.05 to 2 nM. Each different concentration of radioligand
will have a Non-specific and binding vials in triplicate, 6 tubes for each
concentration of radioligand.
Radioligand used for respective opioid receptor:
Mu = [3H] Naloxone
Kappa = [3H] NorBNI
Delta = [3H] Naltrindol

4.

Make the non-specific with cold drug at 0.1 mM, final concentration will
be 0.01 mM, and add 50 μL to the non-specific tubes. You will need
about 1200 μL of cold drug for each rack.
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Non-specific used the following drugs for respective opioid
receptor:
Mu = Naltrexone
Kappa = NorBNI
Delta = Naltrindol
5.

After selecting concentrations of radioligand to use, make a serial dilution
to the appropriate concentrations.

Make the drugs 10 times more

concentrated than final desired concentration.

Add 50 μL to the

appropriate tubes.
6.

Add 100 μL of cells to each tube. Vortex the tubes and place into the
shaking water bath for 90 minutes at 30 °C.

7.

Prepare standards by adding 50 μL of each concentration of radioligand to
4 mL of scintillation fluid (EconoSafe™ Economical Biodegradable
Counting Cocktail) in 7 mL scintillation vials. You will need 3 tubes per
concentration of radioligand so in total there will be 24 standards.

8.

Fill blue racks with scintillation vials leaving the first and last slots open.
You will need 3 blue racks for each rack of tubes.

9.

Before the incubation was complete GF/B glass fiber filters (Brandel)
were placed in the brandel harvester and rinsed with cold 50 mM Tris
buffer (pH 7.2).

10.
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After 90 minutes, remove rack from water bath and incubation was
quenched with cold 50 mM Tris buffer and aspirated and rinsed three
times with cold 50 mM Tris.

11.

Remove filter paper and transfer to scintillation tubes using puncher/filler.
Fill tubes with 4 mL of scintillation fluid and cap.

12.

Label tubes and shake for 30 to 60 mins.

13.

The bound radioactivity was determined by liquid scintillation
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter).

14.

Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots
of deionized water.

B.

One-Site Competition Binding Assay
The main technique used to characterize the naltrexone derivatives synthesized in

our laboratoies by a one-site competition binding assay. In this assay receptors are
incubated with a constant concentration of radiolabeled ligand that is 0.75 to 1 times the
Kd value determined in the saturation binding assay and various concentrations of the
naltrexone derivatives. From this assay the Ki, the affinity of the unlabeled drug of
interest for the receptor which uses the Cheng-Prusoff equation, and EC50, the molar
concentration of the unlabeled drug of interest that produces 50% inhibition of specific
radioligand binding, is determined.103
For each naltrexone derivative, the one-site competition binding assay is done for
the mu-, delta- and kappa-opioid receptors. For the mu-opioid receptor, the MORCHO

119
cells from Dr. Selley’s laboratories (VCU) are used. The kappa-opioid receptor data uses
KORCHO cells from the University of Minnesota. Both the mu- and kappa-opioid
receptor data is analyzed using hill plot between 5 and 95 percent inhibition. The deltaopioid receptor data uses the DORHEK cells from the University of Minnesota for the 6N-heterocyclic substituted naltrexamine derivatives. This set of data is analyzed using
nonlinear regression using Prism, a statistical software package. The 14-O-heterocyclic
substituted naltrexone derivatives delta-opioid receptor data uses the DORCHO cells
from Temple University. This set of data is analyzed by using the hill plot between 5 and
95 percent inhibition.
The buffer uses in this assay is TME buffer without NaCl (24.27 g Tris 50mM),
1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 4 L DI water and pH adjusted to 7.7 at
room temperature). The protein concentration ranges from 9 to 30 μg depending on the
cells being used. For this assay, the concentration of the [3H] radioligand will be 0.75 to
1 times the Kd value determined by the saturation assay. The non-specific binding is
measured with the addition of the same ligand as the radioligand but not labeled with
tritium. The total volume in each tube is 500 μL. For this assay, there are 3 types of
tubes: total binding, non-specific binding, and drugs competition binding. For the total
binding, it will include the cells, radioligand, and TME without NaCl. For non-specific
binding, it will include all of the components in total binding as well as the addition of
cold ligand.

For each rack, 2 different drugs can be tested with 7 different

concentrations. These tubes will include radioligand, cells, drug of interest and TME
with no NaCl. All of these tubes are done in triplicate. A serial dilution of the drugs of
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interest is made 10 times more concentrated than the final concentrations that ranged
from 0.001 nM to 1000 nM. The concentration ranges can be narrowed down to get a
more accurate Ki value.
The basic protocol is very similar to the saturation assay. The general step-bystep protocol for the competition binding assay can be seen below and some changes are
made in certain cases discussed in the discussion and results section.

Preparation of Protein
1.

Remove cells from -80°C freezer and thaw. Add about 5mL of TME
buffer with no NaCl into the centrifuge tube for every cell aliquot used.
NOTE: Keep all buffers, compounds and cells on ice at all times!

2.

Vortex cells to make sure the cells are completely dissolved in the buffer.

3.

Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10
minutes at 10°C.

4.

Pour out the supernatant and keep the pellet. Re-suspend the pellet in
about 3 to 4 mLs of the TME buffer with no NaCl for every tube of cells
used.

5.

Homogenize the cells to make sure they are completely dissolved in the
buffer. Keep the cells on ice.

6.

Conduct the Bradford Protein Determination Assay using BSA (Bovine
Serum

Albumin)

Spectrophotometer.

as

standards

using

a

Beckman

DU

640
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One-site Competition Binding Assay
1.

Propylene culture tubes (12x75 mm) were numbered and placed in racks
on ice.

2.

First, add the appropriate amount of TME with No NaCl to all the culture
tubes. Note: Follow spreadsheet made with concentrations and amounts
of drugs to add to the tubes. Normally final volume will be 500 μL per
tube.

3.

Make the cold drug 10 x more concentrated than the final desired
concentration in TME with no NaCl. So, the concentration should be 100
μM with a final concentration 10 μM. Add 50 μL to the appropriate tubes
in triplicate. This is your non-specific.
Non-specific used the following drugs for respective opioid
receptor:
Mu = Naltrexone
Kappa = NorBNI
Delta = Naltrindol

4.

Make the dilutions of your drugs in TME with no NaCl and add 50 μL of
drug to appropriate tubes. The drugs should be made 10 times more
concentrated than the desired concentration. Also, in the beginning you
should test a wide range before narrowing it down. Note: You can do 2
drugs per rack in triplicate.
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5.

Make the stock solution of the radioligand 10 times more concentrated
than desired concentration in TME with no NaCl. Add 50 μL to all the
tubes. Note: The concentration of radioligand is normally 0.75 to 1
times of its Kd.
Radioligand used for respective opioid receptor:
Mu = [3H] Naloxone
Kappa = [3H] NorBNI
Delta = [3H] Naltrindol

6.

Add 100 μL of cells to each tube. Vortex the tubes and place into the
shaking water bath for 120 minutes at 30 °C.

7.

Prepare standards by adding 50 μL of radioligand to 4 mL of scintillation
fluid (EconoSafe™ Economical Biodegradable Counting Cocktail) in 7
mL scintillation vials in triplicate. Cap and label the standards.

8.

Fill blue racks with scintillation vials leaving the first and last slots open.
You will need 3 blue racks for each rack of tubes.

9.

Before the incubation was complete, GF/B glass fiber filters (Brandel)
were placed in the brandel harvester and rinsed with cold 50 mM Tris
buffer (pH 7.2).

10.

After 120 minutes, remove rack from water bath and incubation was
quenched with cold 50 mM Tris buffer and aspirated and rinsed three
times with cold 50 mM Tris.

11.
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Remove filter paper and transfer to scintillation tubes using puncher/filler.
Fill tubes with 4 mL of scintillation fluid and cap.

12.

Label tubes and shake for 30 to 60 minutes.

13.

The bound radioactivity was determined by liquid scintillation
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter).

14.

Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots
of deionized water.

C.

Functional [35S] GTPγS Assay – Agonism of Compounds Compared with

DAMGO
The [35S]GTPγS functional binding assay measures the level of G-protein
activation following the binding of an agonist to a G-protein coupled receptor. This
assay is useful to measure the functional activity of a ligand for a certain receptor
including potency, efficacy and antagonistic affinity.

Since this assay analyzes the

earliest receptor-mediated events, the measures obtained from the agonist are not subject
to amplification or other modulation that may occur further downstream from the
receptor. From the functional [35S] GTPγS binding assay we can determine the Emax,
the maximum effect of the drug or the efficacy, and the EC50, the molar concentration
that produces 50% of the maximum possible effective response normally for an agonist
or the potency. DAMGO, a full mu-opioid receptor agonist, is used to compare with our
drugs. For this assay, we use TME with NaCl because Na+ decreases spontaneous
receptor activity.
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In the assay, [ S]GTPγS replaces the endogenous GTP that binds to the Gα
35

subunit when the receptor is activated (Figure 31). Since the γ-thiophosphate bond is
poorly hydrolyzed by GTPase, the G-protein is prevented from reforming the
heterotrimer (Figure 32).115 Therefore, the [35S]GTPγS labeled Gα subunits accumulate
and can be measured by counting the amount of [35S]-label incorporated. The Gα subunit
remains associated with the membrane by filtering the preparation through filters and
counting the radioactivity retained on the filter.101

Figure 31. Guanine-nucleotide exchange in G-protein coupled receptor signaling cycle.
(A) Low-affinity state of receptor where G-protein is uncoupled from the receptor. The
agonist binds and induces receptor conformational change. (B) High-affinity state of
receptor where the receptor is coupled to the G-protein, this is also known as the ternary
complex. The ternary complex consists of an agonist, receptor and G-protein. Activation
of receptor will release bound GDP and bind GTP. (C) The Gα subunit of the G-protein
dissociates from the complex and interacts with downstream second messenger elements.
The Gα subunit is turned off when the bound GTP undergoes a hydrolysis reaction to
reform GDP and the receptor returns to inactive state.108
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Figure 32. Chemical Structure of [35S]GTPγS.

For each naltrexone derivative, a functional assay is done for the mu-opioid
receptors. For the mu-opioid receptor, the MORCHO cells from Dr. Selley’s laboratories
(VCU) are used.
The buffer that is used in this assay is TME buffer with NaCl (24.27 g Tris 50
mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 28.38 g NaCl (100 mM), 4L DI
water and pH adjusted to 7.7 at room temperature. The protein concentration ranges from
9 to 10 μg depending of MORCHO cells being used.

For this assay, [35S]GTPγS

radioligand is used and the concentration of the radioligand is made to equal 125,000
DPMs (disintegrations per minute).

The non-specific binding is measured with the

addition of cold GTPγS or not labeled with [35S]. The total volume in each tube is 500
μL. For this assay, there are 4 different conditions: basal, non-specific binding, DAMGO
binding and drug binding. For the basal, it will include the cells, GDP, radioligand, and
TME with NaCl. For non-specific binding, it will include all of the components in basal
binding as well as the addition of cold GTPγS.

For DAMGO, the tubes include

DAMGO, GDP, cells and TME with NaCl. For each rack, 2 different drugs can be tested
one with 6 different concentrations and one with 7 different concentrations. These tubes
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will include radioligand, cells, GDP, drug of interest and TME with NaCl. All of these
tubes are done in triplicate. A serial dilution of the drugs of interest was made 10 times
more concentrated than the final concentrations that ranged from 0.001 nM to 10000 nM.
After an idea of the value of the EC50 has been determined, it is possible to narrow the
concentration ranges to be around that value.
The general step-by-step protocol for the functional binding assay below and
some changes are made in certain cases discussed in the discussion and results section.
Preparation of Protein
1.

Remove cells from -80 °C freezer and thaw. Add about 5mL of TME
buffer with NaCl into the centrifuge tube for every cell aliquot used.
NOTE: Keep all buffers, compounds and cells on ice at all times!

2.

Vortex cells to make sure the cells are completely dissolved in the
buffer.

3.

Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10
minutes at 10 °C.

4.

Pour out the supernatant and keep the pellet. Re-suspend the pellet in
about 3 to 4 mLs of the TME buffer with NaCl for every tube of cells
used.

5.

Homogenize the cells to make sure they are completely dissolved in the
buffer. Keep the cells on ice.

6.
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Conduct the Bradford Protein Determination Assay using BSA (Bovine
Serum

Albumin)

as

standards

using

a

Beckman

DU

640

Spectrophotometer.
GTPγS Functional Binding Assay
1.

Propylene culture tubes (12x75 mm) were numbered and placed in racks
on ice.

2.

First, add the appropriate amount of TME with NaCl to all the culture
tubes. Note: Follow spreadsheet made with concentrations and amounts
of drugs to add to the tubes. Normally final volume will be 500 μL per
tube.

3.

Make the cold GTPγS to 10 μM concentration (final concentration will be
1 μM) according to work up table in TME with NaCl and add 50 μL to the
appropriate tubes in triplicate. Cold GTPγS is used to measure your nonspecific.

4.

Make the dilutions of your drugs and add 50 μL of drug to appropriate
tubes. Note: The drugs should be 10 times more concentrated then the
final concentration. Also, in the beginning you should test a wide range
before narrowing it down. Note: You can make 2 drug in triplicate for
each rack.

5.

Make a 100 μM solution of GDP (final concentration will be 10 μM) in
TME with NaCl and add 50 μL in to all the tubes.

6.
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Make the stock solution of the [ S] GTPγS radioligand with TME with
35

NaCl. Add 50 μL to all of the tubes. Note: For 1 aliquot of [35S]GTPγS,
about 5 μL, you will need around 5 mL of TME with NaCl. Basically,
you need to make your standards to be around 125,000 DPM so check
by adding 50 μL to 4 mL of scintillation fluid (EconoSafe™
Economical Biodegradable Counting Cocktail) in 7 mL scintillation
vials in triplicate and check with scintillation counter.
7.

Add 100 μL of cells to each tube. Vortex the tubes and place into the
shaking water bath for 90 minutes at 30 °C.

8.

Fill blue racks with scintillation vials leaving the first and last slot open.
You will need 3 blue racks for each rack of tubes.

9.

Before the incubation was complete GF/B glass fiber filters, (Brandel)
were placed in the brandel harvester and rinsed with cold 50 mM Tris
buffer (pH 7.2).

10.

After 90 minutes, remove rack from water bath and incubation was
quenched with cold 50 mM Tris buffer and aspirated and rinsed three
times with cold 50 mM Tris.

11.

Remove the rack from the water bath and aspirate the tubes and rinse 3
times with cold tris.

12.

Remove filter paper and transfer to scintillation tubes using puncher/filler.
Fill tubes with 4 mL of scintillation fluid and cap.

13.
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Label tubes and place in counter with a 9 hour delay use program 10 and
place a rack with any 3 vials from any previous assay. Note: Each vial
will be counted for 3 hours.

14.

The bound radioactivity was determined by liquid scintillation
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter).

15.

Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots
of deionized water.

D.

Functional [35S]GTPγS Assay – Competition of Naltrexamine Derivatives

with DAMGO
Next, the step is to determine whether the 6-N-heterocyclic substituted
naltrexamine derivatives were antagonists by conducting a functional [35S] GTPγS assay
where the drug of interest is competing against DAMGO, a full mu-opioid agonist. From
this functional [35S] GTPγS binding assay we can determine the Emax, the maximum
effect of the drug or the efficacy, and the EC50, the molar concentration that produces
50% of the maximum possible effective response normally for an agonist or the
potency.107 DAMGO, a full mu-opioid agonist, is used to compare with our drugs. For
this assay, TME with NaCl is used because Na+ decreases agonist binding and will barely
affect antagonist binding.
For each naltrexone derivative, a functional assay is done for the mu-opioid
receptors. For the mu-opioid receptor, the MORCHO cells from Dr. Selley’s laboratories
(VCU) is used.
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The buffer that is used in this assay is TME buffer with NaCl (24.27 g Tris
50mM), 1.16 g MgCl2 (3 mM), 0.312 g EGTA (0.2 mM), 28.38 g NaCl (100 mM), 4L DI
water and pH adjusted to 7.7 at room temperature). The protein concentration ranges
from 9 to 10 μg depending of MOR CHO cells being used. For this assay, [35S]GTPγS
radioligand is used and the concentration of the radioligand is made to equal 125,000
DPMs (disintegrations per minute).

The non-specific binding is measured with the

addition of cold GTPγS or not labeled with [35S]. The total volume in each tube is 500
μL. For this assay, there are 4 types of tubes: basal, non-specific binding, DAMGO
binding and drug binding. The basal includes the cells, GDP, radioligand, and TME with
NaCl. For non-specific binding, it will include all of the components in Basel binding as
well as the addition of cold GTPγS. For the set of DAMGO, tubes include DAMGO,
GDP, cells and TME with NaCl. There are 7 different concentrations of DAMGO used
ranging from 0.001 to 10 nM. The first set of tubes is just DAMGO and then the last set
of 7 tubes is DAMGO at different concentrations with a single concentration of the drug
of interest. Normally the concentration of the drug of interest is about 10 times its Ki
value.

For each rack, only 1 different drug can be tested. These tubes will include

radioligand, cells, GDP, DAMGO, the drug of interest and TME with NaCl. All of these
tubes are done in triplicate.
For these assays, the Ke value is determined for the drug of interest by comparing
the right shift in the curve produced by the addition of the drug of interest to DAMGO.
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The general step-by-step protocol for the functional competition binding assay of
DAMGO and drug of interest can be seen below. Some changes are made in certain
cases discussed in the discussion and results section.
Preparation of Protein
1.

Remove cells from -80 °C freezer and thaw. Add about 5mL of TME
buffer with NaCl into the centrifuge tube for every cell aliquot used.
NOTE: Keep all buffers, compounds and cells on ice at all times!

2.

Vortex cells to make sure the cells are completely dissolved in the
buffer.

3.

Counterbalance the tubes by weight and centrifuge at 50,000 x g for 10
minutes at 10 °C.

4.

Pour out the supernatant and keep the pellet. Re-suspend the pellet in
about 3 to 4 mLs of the TME buffer with NaCl for every tube of cells
used.

5.

Homogenize the cells to make sure they are completely dissolved in the
buffer. Keep the cells on ice.

6.

Conduct the Bradford Protein Determination Assay using BSA (Bovine
Serum

Albumin)

as

standards

using

a

Beckman

DU

640

Spectrophotometer.
GTPγS Functional Binding Assay
1.

Propylene culture tubes (12x75 mm) were numbered and placed in racks
on ice.

2.
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First, add the appropriate amount of TME with NaCl to all the culture
tubes. Note: Follow spreadsheet made with concentrations and amounts
of drugs to add to the tubes. Normally final volume will be 500 μL per
tube.

3.

Make the cold GTPγS to 10 μM concentration (final concentration will be
1 μM) according to work up table in TME with NaCl and add 50 μL to the
appropriate tubes in triplicate. Cold GTPγS is used to measure your nonspecific.

4.

Make the dilutions of your drugs and add 50 μL of drug to appropriate
tubes. Note: The drugs should be 10x more concentrated then the final
concentration. Also in the beginning you should test a wide range before
narrowing it down. Note: You can make 2 drug in triplicate for each
rack.

5.

Make a 100 μM solution of GDP (final concentration will be 10 μM) in
TME with NaCl and add 50 μL in to all the tubes.

6.

Make the stock solution of the [35S] GTPγS radioligand with TME with
NaCl. Add 50 μL to all of the tubes. Note: For 1 aliquot of [35S]GTPγS,
about 5 μL, you will need around 5 mL of TME with NaCl. Basically,
you need to make your standards to be around 125,000 DPM so check
by adding 50 μL to 4 mL of scintillation fluid (EconoSafe™
Economical Biodegradable Counting Cocktail) in 7 mL scintillation
vials in triplicate and check with scintillation counter.

7.
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Add 100 μL of cells to each tube. Vortex the tubes and place into the
shaking water bath for 90 minutes at 30 °C.

8.

Fill blue racks with scintillation vials leaving the first and last slot open.
You will need 3 blue racks for each rack of tubes.

9.

Before the incubation was complete GF/B glass fiber filters (Brandel)
were placed in the brandel harvester and rinsed with cold 50 mM Tris
buffer (pH 7.2).

10.

After 90 minutes, remove rack from water bath and incubation was
quenched with cold 50 mM Tris buffer and aspirated and rinsed three
times with cold 50 mM Tris.

11.

Remove the rack from the water bath and aspirate the tubes and rinse 3
times with cold tris.

12.

Remove filter paper and transfer to scintillation tubes using puncher/filler.
Fill tubes with 4 mL of scintillation fluid and cap.

13.

Label tubes and place in counter with a 9 h delay use program 10 and
place a rack with any 3 vials from any previous assay. Note: Each vial
will be counted for 3 hours.

14.

The bound radioactivity was determined by liquid scintillation
spectrophotometry (Beckman Coulter LS6500 Scintillation Counter).

15.

Clean Brandel harvester with a little bit of 70% EtOH and rinse with lots
of deionized water.
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4.

Data Analysis of Pharmacological Studies
The competition binding assays are used to determine the affinity of these 14-O-

heterocyclic substituted naltrexone derivatives and 6-N-heterocyclic substituted
naltrexamine derivatives for all three opioid receptors. From the assay, the IC50 values
are determined, and using the Cheng-Prusoff equation, the IC50 values can be converted
into Ki values (Figure 33).103

Ki =

IC
1 + (D/KD)

_____________________
50

Figure 33. Cheng-Prusoff equation. This is the equation to convert the IC50 of a ligand to
the Ki or the concentration required to produce 50% inhibition of the competing
radioligand. The D represents the concentration of radioligand and the Kd is the
dissociation constant of the radioligand binding to the receptor.103

A graphical representation, competition binding curve, is created consisting of the
log concentration of the naltrexone derivative versus the percent of radioligand bound for
each concentration of naltrexone derivative. Only the linear portion of the curve, where 5
to 95% of the radioligand is bound, is considered in determining the IC50 value. IC50 is
determined where the concentration of the competitive ligand produces 50% inhibition of
the competing radioligand (Figure 34).116
The standard error of the mean was determined for each compound and the ratio
between delta- to mu-opioid receptors and kappa- to mu-opioid receptors was
determined.
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Figure 34. Competition binding curve. Binding of a single concentration of labeled
ligand in the presence of various concentrations of unlabeled ligand. The IC50 is
determined where there is 50% radioligand bound to receptor.117
In order to characterize the agonistic activity of these naltrexone derivatives, a
functional binding assay was conducted, and the 14-O-heterocyclic substituted naltrexone
derivatives and 6-N-heterocyclic substituted naltrexamine derivatives Emax values are
compared to the Emax value for DAMGO. Competition binding curves are constructed
from the data where the log concentration of the unlabeled drug is on the x-axis and the
percent stimulation of the receptor by the binding of [35S]GTPγS is on the y-axis. From
the curves, the potency, or EC50, and the intrinsic efficacy, or Emax, are determined. The
EC50 is the molar concentration of an agonist to produce 50% of the maximal possible
effect and the Emax is the maximum effect of the agonist.106 DAMGO has an Emax
value of 366% stimulation of receptor and represents 100% agonist activity. All of the
naltrexone derivatives are compared to DAMGO’s Emax value in order to determine
whether these compounds are agonists, partial agonists or antagonist profiles. Since the
measurement is taken at the first step of activation where GTP binds, amplification is not
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a factor and provided the best source of information about ligand-induced events at the
receptor.118
Stimulation of [35S]GTPγS through binding of an agonist produces a sigmoidal
concentration effect curve (Figure 34). Therefore, the effects of competitive antagonists
can be measured using a similar [35S]GTPγS assay.

The shifts in the agonist

concentration-effect curve for the [35S]GTPγS binding in the presence of a singleconcentration of antagonist can be measured.

A dissociation constant, Ke, for the

antagonist is determined from the right shift in the agonist concentration-effect curve
(Figure 35). From the Ke, the reciprocal can be taken and defined as the affinity of the
antagonist such that when the degree of shift of the agonist dose-response curve is 2 fold,
the –log10Ke=pA2 where Ke is in molar concentration. The pA2 value is the apparent
affinity that is the negative log of the molar concentration of antagonist that makes it
necessary to double the concentration of the agonist needed to elicit the original
submaximal response obtained in the absence of antagonist. This analysis assumes the
antagonist is competitive and not dependent on how the antagonist acts.106,107

[EC50 DAMGO + Antagonist]
Dose Ratio = __________________________________
[EC50 DAMGO]

[Antagonist]
Ke = ________________
(Dose Ratio-1)
Figure 34. Determination of the dose ratio and dissociation constant (Ke). The dose
ratio is determined from the EC50 of DAMGO with a single concentration of antagonist
present over the EC50 of DAMGO by itself. The Ke is determined from the concentration
of the antagonist divided by the dose ratio minus 1.107
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Figure 35. [35S]GTPγS functional competition binding curve. Concntration curve of the
binding of a full agonist at varying concentrations and the addition of a single
concentration of antagonist to produce a right shift in the curve. A dose ratio can be
calculated to determine the dissociation constant, Ke, for the antagonist.117
5.

Molecular Modeling Studies

5.1

Homology Model of the Mu-Opioid Receptor
A homology model of the mu-opioid receptor was built based on the X-ray crystal

structure of bovine rhodopsin (1U19) with a resolution of 2.2 Å.109 A primary sequence
alignment was conducted using Clustal X. Rhodopsin sequence was aligned with the
human mu-opioid receptor sequence as well as human delta- and kappa-opioid receptors
for a more accurate alignment. The helices were identified based the alignment in
reference to the conserved residues in all GPCRs.119

The bovine rhodopsin crystal

structure was downloaded into Sybyl 7.1 from the Protein Data Bank. All seven helices
of bovine rhodopsin were mutated and the N terminus and C terminus of mu-opioid
receptor was cleaved off before Ile68 and after Pro355 respectively. Loop searches were
conducted for EL (extracellular loops) 1, 2 and 3, IL (intracellular loop) 3 and the

beginning of TM (transmembrane) 2.
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It was very important to maintain the same

backbone orientation of rhodopsin in the mu-opioid receptor homology model’s EL2 and
the TM helices part since they were involved in the binding pocket of most GPCRs.
Once the mu-opioid receptor model was generated, SCWRL (Side Chain Placement with
Rotamer Library) was used to minimize sidechain-backbone and sidechain-sidechain
clashes. Since SCWRL broke the disulfide bond between cysteine amino acid residues
130 of TM3 and 180 of EL2, they were rejoined manually. Also, hydrogens are added
and lone pairs of electrons were deleted. Then the receptor model conformation is
minimized and the backbone validation was conducted using ProTable.

ProTable

program was used to check the geometry and stereochemistry of the backbone and
sidechains of the receptor.

5.2

Binding Pocket Modification of the Mu-Opioid Receptor and Ligand

Docking Studies
Compound 22 was manually docked into the binding pocket of MOR because it
has a very high binding affinity to MOR (Ki = 1.439 nM) among all of the 14-Oheterocyclic substituted naltrexone derivatives. Site-directed mutagenesis data was used
in order to position this compound within the mu-opioid receptor and to help characterize
the binding pocket.106,116

First, the protonated nitrogen near the cyclopropylmethyl

group may form hydrogen bond or have ionic interaction with carboxyl group of Asp149
located on TM3 of MOR. It was reported that the Tyr150 residue locating also on TM3
might interact with the phenolic moiety at the third position of the naltrexone derivative.
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The aromatic moiety Phe223 located on EL2 may also interact through hydrophobic
interactions with the phenolic moiety at the third position of the naltrexone derivative. It
has been reported that Trp320 located on TM7 has a hydrophobic interaction with the
piperidinyl and cyclohexanonly rings in the naltrexone skeleton. Finally, Tyr328 also
located on TM3 was shown to be an important recognition site for naltrexone through
mutation to a phenyalanine which shows decreased binding affinity to naltrexone.
Tyr328 might interact with the protonated amine and the C14 hydroxyl group of the
naltrexone skeleton.
The compound was then merged into the receptor and locked into place. Another
round of minimization is conducted to get the receptor into the lowest energy
confirmation possible. The receptor is minimized for 100,000 iterations using GasteigerHückel charges and a dielectric constant of 4.0.
Dynamic simulations were also run for 100,000 iterations, snapshots were taken
every 25 fs, with Gasteiger-Hückel charges and a dielectric constant of 4.0. In addition to
these normal settings for a molecular dynamics run of a membrane protein, an aggregate
was setup around the ligand in order to keep the receptor from falling apart. Therefore, a
radius of 8.0 Å is setup around the ligand and this area is the only part of the receptorligand complex that underwent dynamics simulation.

When the simulation was

complete, the last 2000 fs of the receptor was combined and minimized using the
previous settings. The ligand was removed from the receptor and the 14-O-heterocyclic
substituted naltrexone derivatives underwent docking studies.
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All of the 14-O-heterocyclic substituted naltrexone derivatives were drawn into
Sybyl 7.1 with a protonated amine and their conformations are minimized. GOLD
(Genetic Optimization for Ligand Docking) 3.1 was used to perform docking studies for
all of the ligands. The default settings were used and the active site radius was set to 15
Å measured from O1278, C1277, and O1279 from Asp149.

Next, the distance

constraints of 2 to 4 Å were set between O1278 to the positively charged nitrogen of the
naltrexone derivatives. The best docking solutions of all the ligands were assessed using
Sybyl 7.1.
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